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Endothelial dysfunction is due in part to the decrease in the biosynthesis and the 
bioavailability of nitric oxide (NO) in the endothelial cell layer. The chronic exposure of 
blood vessels to cardiovascular risk factors such as LDL-cholesterol, free fatty acids, 
homocysteine and conditions of hyperglycemia can give rise to endothelial dysfunction. 
Many of these same risk factors have also been shown to induce endoplasmic reticulum 
(ER) stress, in endothelial cells. However, the potential links between endothelial 
dysfunction and ER-stress have not been clearly established. 
The present study was undertaken with two objectives. Objective 1 was to 
determine how increased plasma membrane cholesterol content can affect NO diffusion, 
dynamics and signalling. Objective 2 was to determine whether the unfolded protein 
response mediated by ER stress can lead to increase in plasma membrane cholesterol in 
endothelial cells, how ER stress leads to increase in plasma membrane cholesterol and 
whether increase in plasma membrane cholesterol can influence eNOS activity and 
localization in the endothelial cells. 
Objective 1 was carried out by taking Normal Human Fibroblasts (NHF1) and 
sterol transport-defective Niemann Pick type Cl(NPCl) fibroblasts which exhibit 
iv 
increase plasma membrane cholesterol content. NPC1 fibroblats showed decreased 
activation of both intracellular sGC and VASP (Ser239) phosphorylation induced by 
exposure to exogenous NO exposure relative to their normal human fibroblasts (NHF) 
counterparts. 
Objective 2 was to understand the underlying Unfolded Protein Response (UPR)/ 
ER stress-mediated mechanisms responsible for the induction of endothelial dysfunction. 
We observed that ER stress and oxidative stress collectively cause elevations in plasma 
membrane cholesterol in endothelial cells and aortic cross-sections of ER stressed 
C57BL6 mice. The rise in plasma membrane cholesterol was associated with decreased 
eNOS activity, eNOS phosphorylation and increased eNOS localization to the Golgi. 
Interestingly, we observed that neutral sphingomyelinase 2 (NSMase2) becomes 
dysfunctional during ER stress and by S-nitrosation of cysteine and nitration of tyrosine 
residues. 
This study is the first in its kind which links the attenuation of endothelial NO 
production to ER stress-mediated increases in plasma membrane cholesterol and 
implicates a key role for NSMase2 in this process. 
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1.1 Endothelial Dysfunction 
Endothelial dysfunction is characterized by an imbalance between 
relaxing and contracting factors, between anticoagulant and procoagulant 
substances, between anti-inflammatory and proinflammatory mediators or 
between growth inhibiting and promoting factors. Such dysfunction can result 
from the mechanical and biochemical injury to the endothelium. Physical damage 
of the endothelium is mostly caused by hypertension; several other risk factors 
such as hypercholesterolemia, diabetes and smoking probably cause injury to the 
endothelium through biochemical mechanisms. Therefore, vessel wall damage 
may result in endothelial dysfunction and can be clinically manifested as 
thrombosis and atherosclerosis [Rubanyi, et al., 1993]. 
1.1.2 Physiological functions of the endothelial cells 
A defining feature of endothelium is its capacity to keep blood in a fluid 
state [Arnout, et al., 2006]. The coagulation cascade is initiated by the generation 
of an enzyme complex consisting of factor Vila, an active protease and a catalytic 
accelerator termed tissue factor (TF), which catalyzes the conversion of inactive 
clotting factors IX and/or X to active proteases, factors IXa and Xa respectively. 
Factor Xa uses factor Va as a cofactor and converts prothrombin to thrombin, an 
active protease that cleaves plasma fibrinogen to fibrin. Fibrin then self-assembles 
2 
into a blood clot and the process is called thrombosis (Figure 1.1). The various 
active protease complexes of coagulation assemble on the platelet membrane 
surface which has exposed negatively charged phospholipids (phosphotidylserine) 
headgroups. In these activated platelets an enzyme called scramblase mediates 
transport of phosphotidylserine from inner leaflet of plasma membrane to outer 
leaflet. Endothelial cells (ECs) help in inhibiting coagulation by sequestering 
phosphotidylserine on the inner leaflet of their plasma membrane, depriving 
clotting factors of access to a suitable phospholipid surface. Degranulation of 
platelets provides another important source of a phosphotidylserine-rich surface. 
ECs prevent platelet degranulation by acting upon the three principle signals that 
activate platelets: They (a) express ectoenzyme such as endothelial-ADPase that 
degrade the activating that degrade the platelet activator, ADP (b) inhibit 
thrombin, in endothelial cells thrombomodulin, an integral membrane protein is 
bound to thrombin which activates protein C, an inhibitor of coagulation cascade. 
This activated protein C then inactivates factors Va and Villa of the coagulation 
cascade, and (c) prevent exposure of subendothelial collagen. Endothelial cells 
produce a protein called von Willebrand factor (vWF), a cell adhesion ligand, 
which helps endothelial cells adhere to collagen in the basement membrane. Uner 
physiological condtions, collagen is not exposed to the bloodstream. vWF is 
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secreted constitutely int the plasma by endothelial cells and is stored in granules 
within the endothelial cells and platelets. When the endothelial layer is injured, 
collagen and vWF from the subendothelium is exposed to the bloodstream and 






Figure 1.1 Platelet aggregation cascade 
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A second important function of ECs is the control of blood flow in the 
arterial circulation [Busse, et al., 2006]. Tissue perfusion depends on cardiac 
output and on vascular resistance and this resistance is maintained by the tone of 
smooth muscle cells (SMCs) in conduit arteries. ECs are electrically coupled with 
these SMCs via gap junctions, permitting regulation of membrane potential and 
intracellular Ca2+ levels, but they also release diffusible regulators of SMC tone. 
Two of the most important of these are the vasodilators NO and arachidonic acid 
metabolites known as endothelium-derived relaxing factors, which regulates SMC 
membrane potential. NO is generated by endothelial nitric oxide synthase (eNOS) 
that converts arginine to citrulline, releasing NO [Sessa, et al., 2004] NO relaxes 
SMCs principally by activating soluble guanylate cyclase, which generates cGMP 
and activates protein kinase G. ECs also causes vasoconstriction by producing 
vasoconstrictors, peptides such as endothelin I and angiotension II thus, the 
precise balance of vasodilators and vasoconstrictors is regulated in part by ECs. 
A third important physiological function of ECs is quiescence of the 
inflammatory response by failing to express adhesion molecules that promote 
capture and transmigration of blood leukocytes into tissues. ECs and platelets 
express selectins shortly after cytokine activation by tissue macrophages. 
Activated ECs initially express P-selectins molecules, but within few hours after 
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P-selectins activation E-selectins expression occurs. Endothelial selectins bind to 
carbohydrates on macrophage transmembrane glycoproteins such as sialyl-
Lewisx. In unactivated endothelial cells P-selectins is stored in granules Weibel-
Palade bodies and a-granules in unactivated platelets. [Ley, et al., 2006]. 
1.1.3 Endothelial dysfunction and its relationship to endothelial cell injury 
and death 
The endothelial cell death mostly occurs by apoptosis, a kind of 
programmed cell death [Kerr, et al., 1972]. The features of apoptosis include 
plasma membrane vesiculation, nuclear condensation and nuclear fragmentation. 
An early biochemical indicator of apoptosis is the exposure of phosphotidylserine 
head groups on the outer leaflet of the plasma membrane-lipid bilayer, a change 
that can be detected experimentally by binding of exogenously added annexin V. 
Apoptotic cells cleave genomic DNA into hi stone-covered segments of 
approximately 200 bps known as nucleosomes [Compton, et al., 1992]. Apoptotic 
death is caused by the cleavage of critical cellular proteins by a family of 
structurally related intracellular proteases known as active cysteinyl, aspartyl-
directed proteases (caspases) [Logue, et al., 2008]. Caspase cleavage of inhibitor 
of caspase-activated DNAse (iCAD) releases active endonucleases, known as 
CAD, from inactive complex. CAD then cleaves genomic double-stranded DNA 
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at the segments separating histone-bound nucleosomes, releasing free 
nucleosomes. When the endothelial cells detach from their basement membrane a 
caspase dependent apoptosis is triggered and the phenomenon is referred to as 
anoikis [Gilmore, et al., 2005]. However, certain other forms of endothelial cell 
death depend on intracellular pathways other than caspases, but they share with 
apoptosis the characteristic of being programmed. For example endothelial cells 
may respond to certain signals by the activation of cathepsin B in their cytosol, 
leading to mitochondrial release of apoptosis-inducing factor (AIF) [Li, et al., 
2005]. This protein (AIF) causes DNA degradation and endothelial cell death 
independently of caspases, with dying cells displaying nuclear condensation but 
not fragmentation. 
However, having described about endothelial cell death, it is important to 
know how injurious stimuli trigger endothelial cell death. Several environmental 
stresses play a part in this including oxidative stress, endoplasmic reticulum (ER) 
stress and metabolic stress. 
1.1.3.1 Oxidative stress 
Reactive Oxygen Species (ROS) includes highly reactive molecules that 
are generated from the partial reduction of molecular oxygen, including 
superoxide and its dismutated product H2O2. The most potent pathway for 
7 
generating ROS is catalyzed by the phagocyte oxidase (Phox) complex, which is 
expressed by neutrophils and macrophages. In addition to Phox, endothelial cells 
also express nonphagocyte NADPH dependent oxidase (Nox) complexes. Rodent, 
but not human, endothelial cells express xanthine oxidase (XO), an alternative 
mechanism for generating H2O2 but human endothelial cells (EC) may take up XO 
from plasma. The endogenous ROS generating systems in endothelial cells 
contribute more in generating second messengers that regulate EC growth, 
proliferation, EC barrier function, vasorelaxation and vascular remodelling [Rhee 
et al,. 2000] rather than producing oxidative stress. However, the endogenous Nox 
enzymes have also been considered to cause EC dysfunction in the pathogenesis 
of hypertension, atherosclerosis, cardiac hypertrophy and heart failure [Keaney, 
et al,. 2005]. Increasing evidence supports the idea that ROS generated from 
mitochondria significantly contribute to EC dysfunction and the progression of 
atherosclerosis [Nishikawa, et al, 2003]. 
Mitochondrial electron transport chains consume oxygen by oxidative 
phosphorylation to form ATP. During this process, between 0.4 and 4% of the 
consumed oxygen is released in the mitochondria as ROS, resulting from the 
univalent reduction of molecular oxygen to superoxide anion (O'2") by electrons 
that leak from complex I and III of the mitochondrial electron transport chain. O-2" 
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is in turn converted to H2O2 by mitochondria-specific manganese-dependent 
superoxide dismutase. H2O2 is a mild oxidant and is readily converted to the 
powerful hydroxyl radical (OH) via the Fenton reaction. 0 '2 \ H2O2 and OH cause 
multiple cellular actions if they are not appropriately regulated [Balaban, et al, 
2005]. In ECs, NO appears to be one of the major targets of ROS and its 
consumption results in EC dysfunction. Not only does O'2" alter endothelium-
dependent vascular relaxation through interaction with NO, but the resultant 
formation of peroxynitrite can also oxidize the essential eNOS cofactor 
tetrahydrobiopterin (BH4) and promote eNOS uncoupling [Landmesser, et al, 
2003]. For proper function of eNOS, BH4 is essential in many ways including 
stabilizing the eNOS dimer and increasing the affinity of eNOS for L-arginine. In 
ECs native LDL [Pritchard, et al. 1995], oxidized LDL [Vergnani, et al, 2000] 
can stimulate the O' " production and hypercholesterolemia can also increase 
vascular O'2- production via NADPH oxidase [Warnholtz, et al. 1999] and/or 
xanthine oxidase [Ohara, et al, 1993]. O'2" produced reacts with NO to form 
peroxynitrite [White, et al, 1994] which in turn oxidizes the active eNOS cofactor 
BH4 to cofactor-inactive molecules such as BH2 [Laursen, et al, 2001], thus 
limited availability of BH4 would result in uncoupling of eNOS. 
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The biochemical responses that couple oxidative stress to apoptosis are 
increasingly well understood. Many of these responses are mediated by p38 
mitogen-activated protein kinase (p38 MAPK) and/or by c-Jun N-terminal kinase 
(JNK), both of which may be activated by kinase cascades initiated by apoptosis-
signalling kinase I (ASKI) and ASK I may be a common target of multiple types 
of stress leading to apoptosis. 
1.1.3.2 Endoplasmic Reticulum Stress (ER stress) 
Endoplasmic reticulum is an important site in the cell where the protein 
folding and modification takes place. ER also marks unfolded or misfolded 
proteins for their degradation. However, when a cell meets any adverse condition 
and is not able to function normally and unfolded protein response (UPR) is 
triggered in the ER and this phenomenon is termed as ER stress. ER stress is 
described in detail in section 1.4. 
1.1.3.3 Metabolic Stress 
ECs supply nutrition and oxygen to tissues, and may themselves 
experience stresses from abnormal metabolism (e.g., high glucose and high lipid 
levels), energy depletion or hypoxia. Insulin resistance, defined as decreased 
sensitivity and responsiveness to metabolic actions of insulin that promote glucose 
disposal, is an important consequence of metabolic stress to ECs. Insulin 
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resistance is observed in diabetes, glucose intolerance and dyslipidemias as well as 
in oxidative stress and inflammation. Normal insulin receptor/IGF 1 receptor 
signal transduction is well characterized [Saltiel, et ai, 2001]. These receptors 
have intrinsic protein tyrosine kinase activity that is activated by ligand binding. 
The activated receptors phosphorylate several substrates, including insulin 
receptor substrate 1 (IRS 1), which leads to activation of phosphatidylinositol-3-
kinase (PDK)-Akt which leads to activation of the Ras-Raf-ERK signalling 
cascades. The PI3K-Akt pathway is the major branch of insulin signalling that 
regulates metabolic function, triggering glucose transporter 4 (GLUT4) 
translocation to the plasma membrane, where it mediates glucose uptake in 
skeletal muscle and adipocytes. Thus, IRSl/Akt activation underlies the molecular 
mechanism for insulin resistance and diabetes. 
Hyperglycemia may induce expression of extracellular matrix and 
procoagulant proteins, increase EC apoptosis, decrease EC proliferation and 
inhibit fibrinolysis. Similarly, free fatty acids (FFAs) also inhibit EC proliferation 
and increase EC apoptosis. 
Hypoxia is another source of metabolic stress that has not been extensively 
studied in ECs. ECs constitutively synthesize NO, which can regulate cellular 
oxygen consumption and the mitochondrial redox state. Recently it has been 
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proposed that in ECs, inhibition of mitochondrial oxygen consumption by NO 
may lead to metabolic hypoxia, a condition in which cells are unable to use 
available oxygen and are directed to apoptosis [Moncada, et al., 2002]. 
1.1.4.1 Indicators of Endothelial dysfunction 
Endothelial injury may result in the release of various factors that can be 
detected in the circulation and can be potentially used as markers of endothelial 
dysfunction. 
Endothelin-1 
Endothelin-1 is an endothelium derived peptide that has powerful 
vasoconstrictor properties. Increased levels of endothelin-1 have been 
demonstrated in conditions associated with endothelial dysfunction such as 
atherosclerosis, hypercholesterolemia and cigarette smoking [Lerman, et al, 
1991]. Furthermore, oxidized low-density lipoprotein has been shown to stimulate 
endothelin-1 production and secretion [Boulanger, et al, 1992]. Injury to vascular 
endothelial cells probably triggers the release of endothelin-1 and therefore it has 
been suggested that the levels of circulating endothelin in plasma may represent a 
marker of endothelial dysfunction. Because endothelin-1 also has mitogenic 
properties, it may also play a role in the development of premature atherosclerosis. 
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von Willebrand factor 
The von Willebrand factor (vWF) is a glycoprotein synthesized mainly by 
vascular endothelial cells. It has important functions in hemostasis, participating 
in the coagulation and in the formation of platelet plugs at the sites in patients 
with hypercholesterolemia. Its levels are elevated in situations characterized by 
vascular damage with injury of the endothelium and it has been suggested that the 
injured endothelial cells leak vWF leading to increased plasma levels. 
Tissue plasminogen activator and plasminogen activator inhibitor-1 
Tissue plasminogen activator is a protein released by endothelial cells. It 
activates the reaction in which plasminogen activator regulates the fibrinolytic 
activity of blood in balance with plasminogen activator inhibitor-1, another 
product of endothelial cells serving as the primary inhibitor of tissue plasminogen 
activator. These circulating vascular endothelial markers are elevated in 
hypercholesterolemia [Geppert, et al, 1998]. 
1.1.5 Endothelial dysfunction in atherosclerosis 
Endothelial injury is regarded as an important early event in atherogenesis 
[Ross et al, 1990]. The consequence of endothelial damage that initiate fatty 
streak and plaque formation include increased adherence of monocytes, increased 
permeability to monocytes/macrophages and lipoproteins that accumulate in the 
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vessel wall, increased platelet adherence and increased smooth muscle cell 
migration and proliferation [Henderson et al, 1991]. Endothelial dysfunction may 
also be accompanied by decreased availability of local NO. This may be due to 
decreased endothelial production of NO or to excess production of superoxide 
anions or both with consequent degradation of NO before it can reach its target 
tissues. Because NO is a local vasodilator that also inhibits platelet adherence and 
aggregation, smooth muscle proliferation and endothelial cell leucocyte 
interactions, reduced NO activity may also contribute to the initiation and 
progression of atherosclerosis [Cooke, et al, 1994]. In hypercholesterolemia, 
superoxide production is enhanced with consequently decreased bioavailability of 
NO [Ohara, et al. 1993]. 
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1.2 Cholesterol 
Cholesterol is an alicyclic lipid molecule, the structure of which contains 
four fused rings (all trans-anti), a single hydroxyl group at carbon 3, a double 
bond between carbons 5 and 6, and an iso-octyl side chain at carbon 17 (Figure 
1.2). The 3P-OH function of cholesterol is important, since a fatty acid can be 
esterified to this position. Cholesterol is an essential component of cellular plasma 
membranes in higher organisms. The plasma membranes have been reported to 
contain from about half to as much as 90% of the total cellular unesterified 
cholesterol [Lange, et al., 2000]. Since membrane cholesterol is unesterified, the 
free 30 -OH group of cholesterol may engage in hydrogen bonding with water and 
possibly with co-lipids in the membrane. It is suggested that the capacity of 
plasma membranes to solubilise cholesterol is largely a function of its 
sphingomyelin content. 
Figure 1.2 Structure of cholesterol 
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1.2.1 Cholesterol and sphingomyelin interaction 
In cell membranes sphingolipids (sphingomyelin and glycosphingolipids) 
and cholesterol act as platforms for different cellular processes. There occurs a 
lateral interaction among sphingolipids and cholesterol to induce the formation of 
microdomains or rafts which helps in the recruitments of certain proteins to these 
domains as well as in the association of GPI-anchored proteins to plasma 
membrane invaginations, the caveolae. Cholesterol is assumed to associate with 
the rafts either by functioning as a spacer within the sphingolipid domains or by 
associating specifically with proteins (e.g. caveolin) in certain membrane domains 
(caveolae) [Murata, et al,. 2002]. There occurs specific cholesterol-sphingomyelin 
interaction in membranes which is stabilized by hydrogen bonds between the 3P-
OH group of cholesterol and the amide-linkage in sphingomyelin. 
1.2.2 Cholesterol and sphingomyelin homeostasis 
Cholesterol and sphingomyelin in biological membranes affect each 
other's homeostasis. The incorporation of sphingomyelin mass from liposomes 
into membranes results in the net flow of cholesterol from intracellular sites where 
it is stored as cholesteryl esters to the plasma membrane compartments. This is 
also accompanied by reduced acyl Co A: cholesterol acyltransferase (ACAT)-
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catalyzed esterification of cell cholesterol and an increased formation of newly 
synthesized cholesterol. Also the degradation of sphingomyelin mass (with the aid 
of exogenous sphingomyelinase) leads to a dramatic activation of the endogenous 
ACAT-catalyzed esterification of cholesterol in endoplasmic reticulum [Slotte, et 
al, 1988]. 
1.2.3 Biosynthesis of cholesterol 
Cholesterol is made from acetyl-CoA. The process occurs in four steps, 
step 1. the three acetate units condense to form a 6-carbon intermediate 
mevalonate, step 2. mevalonate is converted into activated isoprene units, step 3. 
six 5-carbon isoprene units polymerize to form the 30-carbon linear structure of 
squalene, step 4. the cyclization of squalene forms the four ring steroid nucleus 
and further series of changes such as oxidation, removal or migration of methyl 
groups leads to the formation of final product- cholesterol. 
1.2.3.1 Synthesis of mevalonate from acetate 
The first step in cholesterol biosynthesis leads to the intermediate 
mevalonate. Two molecules of acetyl-CoA condense, forming acetoacetyl-CoA, 
catalyzed by thiolase. Acetoacetyl-CoA condenses with a third molecule of acetyl-
CoA to yield the 6-carbon compound P-hydroxy-acetyl- P-methylglutaryl-CoA 
(HMG-CoA), catalyzed by HMG-CoA synthase. In the third reaction, HMG-CoA 
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is reduced to mevalonate by HMG-CoA reductase, an integral membrane protein 
of smooth endoplasmic reticulum. 
1.2.3.2 Conversion of mevalonate to two activated isoprenes 
The phosphate groups from 3 ATP molecules are transferred to 
mevalonate. In the next step, the phosphate attached to the C-3 hydroxy group of 
mevalonate in the intermediate 3-phospho-5-pyrophomevalonate and the nearby 
carboxyl group both leave, producing a double bond in the 5-carbon product A3-
isopentanyl pyrophosphate the first of the activated isoprenes. Isomerization of 
A3- isopentanyl pyrophosphate yields an activated isoprene dimethylallyl 
pyrophosphate. 
1.2.3.3 Condensation of six activated isoprene units to form squalene 
Isopentyl pyrophosphate and dimethylallyl pyrophosphate undergoes a 
"head-to-tail" condensation in which one pyrophosphate group is displaced and a 
10-carbon chain, geranyl pyrophosphate is formed. Geranyl pyrophosphate 
undergoes another head-to-tail condensation with isopentenyl pyrophosphate, 
yielding the 15-carbon intermediate farnesyl pyrophosphate. Finally, two 
molecules of farnesyl pyrophosphate join head to head forming squalene. 
1.2.3.4 Conversion of squalene to the four-ring steroid nucleus 
The action of enzyme squalene mono oxygenase adds one oxygen atom 
from O2 to the end of the squalene chain, forming an epoxide, squalene 2,3-
epoxide, which is cyclised to a steroid nucleus, resulting in the formation of 
lanosterol. Lanosterol is finally converted into cholesterol in a series of 20 
reactions, including the migration of some methyl groups and removal of others. 
1.2.4 Cholesterol is transported to plasma lipoproteins 
Cholesterol and cholesteryl esters, like triacylgylcerols and phospholipids 
are insoluble in water. Those lipids must be moved from the tissues where they are 
synthesized/absorbed, liver/intestine to the tissues in which they will be stored or 
consumed. They are carried in the blood plasma from one tissue to another as 
plasma lipoproteins, molecular aggregates of specific carrier proteins called 
apolipoproteins with various combinations of phospholipids, cholesterol, 
cholesteryl esters and triacylglycerols. Apolipoproteins combine with lipids to 
form several classes of lipoprotein particles, spherical aggregates with 
hydrophobic lipids at the core and the hydrophilic side chains of protein amino 
acids at the surface. Differing combinations of lipid and protein produce particles 
of different density and sizes such as very low density lipoproteins (VLDL), low 
density lipoproteins (LDL) and high density lipoproteins (HDL). Each class of 
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lipoprotein has a specific function, determined by its point of synthesis, lipid 
composition and apolipoprotein content. The protein components act as signals, 
targeting lipoproteins to specific tissues or activating enzymes that act on the 
lipoproteins. 
When the diet is rich in fatty acids than what are needed immediately as 
fuel, they are converted into triacylglycerols in the liver and packaged with 
cholesterol, cholesteryl esters as well as specific apoproteins such as apoB-100, 
apoC-I, apoC-II, apoC-III and apoE into very low density lipoproteins (VLDL). 
Excess carbohydrates in the diet is also converted into triacylglycerols in the liver 
and exported as VLDLs. The lipoproteins are transported in the blood from liver 
to the adipose tissues where activation of lipoprotein lipase by apoC-II causes the 
release of free fatty acids from triacylglycerols of the VLDLs. Adipocytes take up 
these fatty acids, resynthesizes triacylglycerols from them and store 
triacylglycerols in intracellular droplets. 
The loss of triacylglycerols converts VLDL to low density lipoprotein, 
LDL. These are very rich in cholesterol, cholesteryl esters and apoB-100 as the 
major apolipoprotein. LDL carry cholesterol to peripheral tissues (other than liver) 
that have specific surface receptors called LDL receptors and recognize apoB-100. 
The high density lipoprotein, HDL, is synthesized in the liver as small 
protein rich particles, containing little cholesterol, cholesteryl esters and apoC-I 
and apoC-II as the major apolipoproteins as well as the enzyme lecithin-
cholesterol acyl transferase (LCAT) which catalyzes the formation of cholesteryl 
esters from lecithin (phosphotidylcholine) and cholesterol. The nascent HDL in 
the blood stream collects cholesteryl esters from other circulating lipoproteins and 
LCAT on their surface converts phosphotidylcholine and cholesterol from 
lipoproteins to cholesteryl esters, which enter the interior of nascent HDL, 
converting it from flat disc to sphere- a mature HDL. These cholesterol esters rich 
HDL then returns to liver, where the cholesterol is unloaded and some of it 
converted into bile salts and the rest stored as cholesteryl esters in lipid droplets in 
the cytosol. 
1.2.5 Influx of exogenous cholesterol 
Cholesterol can be endocytosed from lipoproteins in the circulation by 
mechanisms involving desorption- transfer of cholesterol from lipoproteins to the 
exoplasmic leaflet of the plasma membrane bilayer- or by receptor-mediated 
uptake. The best understood process is the one involving serum low density 
lipoprotein (LDL), and it's LDL-receptor. Cholesterol is endocytosed in LDL via 
LDL receptors in the clathrin- coated pits in the plasma membrane to sorting 
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endosomes where it is released from its receptor and the LDL-receptor recycles to 
the cell surface. In the sorting endosomes cholesteryl esters are hydrolyzed to 
cholesterol by cholesterol esterase and transported to the cell surface via a rapid 
route or through slower circuits involving recycling endosomes. Cholesterol is 
transported to late endosomes and then to lysosomes with NPC 1 protein [Neufeld, 
et al, 1996 Higgins, et al, 1999 Puri, et al 1999] that can fuse with each other. 
These endosomal compartments then communicate with the exocytic pathway 
with the help of Trans Golgi Network (TGN) [Cruz, et al, 2000 Lange, et al. 
1989]. The NPC 1 protein is a multispanning membrane protein that contains a 
putative sterol-sensing domain in the membrane spans [Davies, et al 2000]. One 
potential function of the sterol-sensing domain in NPC 1 is to direct cholesterol 
binding and NPC 1 protein may function to remove cholesterol from the 
degradative endosomal compartments by facilitating sterol transport to the Golgi 
or other destinations in vesicular carriers [Liscum, et al, 2000 Blanchette-Mackie, 
et al. 2000]. Some of the cholesterol is also transported to the ER, where it is 
esterified by the enzyme acyl-coenzyme A: cholesterol acyl transferase (ACAT) 
[Liscum, et al, 1999]. This esterification is activated as a means to detoxify 
excess free cholesterol and the esters are deposited in cytosolic lipid droplets, 
from where cholesterol can be mobilized upon ester hydrolysis. This transport to 
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the ER can be mediated by two pathways. One involves the Golgi complex 
whereas the other pathway bypasses the Golgi and the cholesterol from the 
endosomes reaches ER by a protein carrier [Neufeld, et al, 1999. Underwood, et 
al, 1998]. 
1.2.6 Cholesterol efflux from cells 
Cellular cholesterol is effluxed by release of cholesterol to circulating 
lipoproteins at the rate of 0.1% of total cholesterol per min [Johnson, et al, 1991]. 
The release from plasma membrane can take place by desorption into lipoproteins 
or be induced after HDL binding to membrane receptors [Rothblat, et al, 1999]. 
Liver and intestine release cholesterol to the circulation mostly as esters by 
synthesizing and searching lipoproteins [Olofsson, et al, 1999]. Cholesterol can 
be removed by plasma membrane by shedding [Dolo, et al, 2000]. The candidate 
protein involved in cholesterol efflux by HDL is the ATP- binding cassette 
transporter (ABCA 1) [Bodzioch, et al, 1999. Brooks- Wilson, et al, 1999. Rust, 
et al, 1999]. ABCA 1 helps in translocating cholesterol from cytoplasm to the 
exoplasmic bilayer- leaflet from where efflux takes place. 
1.2.7 Regulation of cellular cholesterol levels 
The best known mechanism involved in cholesterol homeostasis is the 
control of cholesterol biosynthesis. This control system involves membrane-
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bound transport factors called sterol regulatory element binding proteins 
(SREBPs) that activate genes upregulating cholesterol uptake and synthesis. The 
SREBP is present in the ER membrane and cycles between ER and the Golgi. It 
can be released from the ER membrane by two proteolytic cleavage. The 
movement of SREBP is dependent on a factor, the SREBP cleavage activating 
protein (SCAP) that contains a sterol- sensing domain regulating the transport. 
When cholesterol levels fall, the SREBP-SCAP complex moves from the ER to 
the Golgi, where two site specific proteases SIP and S2P to liberate the active 
SREBP for transport to the nucleus. The sterol deprivation discharges SREBP-
SCAP complex into the Golgi [Nohtufft, et al, 2000]. 
Another point of regulation is at the plasma membrane level. Plasma 
membrane contains cholesterol in the lipid raft domain and in the liquid disordered 
domain. In the liquid ordered or the lipid raft domain, cholesterol is in 1:1 balance 
with sphingomyelin. Increasing cholesterol levels beyond saturation limit of rafts 
would lead to an increased cholesterol concentration in the liquid- disordered 
phase. This latter pool of cholesterol is free to move back to the ER, thus blocking 
transport SREBP-SCAP to the Golgi. This slows down cholesterol synthesis and 
leads to push extra cholesterol from plasma membrane to ER for esterification and 
is stored as cholesteryl esters in cytosolic lipid droplets. The enzyme 
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sphingomyelinase regulates this process which degrades sphingomyelin that leads 
to a rapid increase in ER cholesterol and eventually cholesteryl ester formation 
[Slotte, et al, 1988. Scheek, et al, 1997]. 
The sphingomyelin and cholesterol levels are controlled together with 
oxysterols. [Ridgway, et al, 2000]. Oxysterols are produced by sterol hydrolases 
from cholesterol. The molecule 25-OH-cholesterol is known to bind to the 
oxysterol-binding protein (OSBP). OSBP resides in the cytosol or the Golgi and is 
regulated by the cellular cholesterol content. Cholesterol depletion leads to 
translocation of OSBP to the Golgi complex and to activation of both cholesterol 
and sphingomyelin synthesis [Ridgway, et al., 1992. Ridgway, et al, 1998]. 
Cholesterol is also metabolized in most tissues of the body. The liver plays 
a key role in eliminating cholesterol that has been removed from the periphery by 
incorporation into circulating high-density lipoproteins. These are taken up by 
scavenger receptor Bl in the liver [Trigatti, et al, 2000], and then part of the 
released cholesterol is metabolized to bile salts and eliminated by secretion 
[Cohen, et al, 1999. Oude Elferink, et al, 1999]. 
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1.3 Nitric Oxide 
Over the past decade or so, NO a free radical gas has been implicated in 
many physiological and pathological processes [Moncada, et al, 1991]. NO plays 
a central role in cardiovascular system as the endothelium derived relaxing factor 
[Furchgott, et al, 1980], within the central nervous system in the signal 
transduction pathways for memory formation, sensory processing and the 
regulation of cerebral blood flow [Xu, et al, 1998] and also in the immune 
defence network [Wagner, et al, 1984]. NO is a diatomic free radical molecule 
and is produced by a family of NOS enzymes. These enzymes require a panel of 
substrates and cofactors to fully function. NO-generating reaction requires L-
arginine, NADPH and oxygen as substrates and tetrahydrobiopterin (BH4), thiol, 
flavin adenine dinucleotide (FAD) and flavin mononucleotide (FMN) as cofactors 
(Figure 1.3). In addition to NO, NOS catalyzed reaction produces citrulline and 
NADP as co-products. The family of isoforms consists of: nNOS (the first to be 
purified and cloned, hence also called NOS1), iNOS (NOS2), and eNOS (NOS3). 
Each isoform is the product of a distinct gene [Hammadi, et al, 2008]. 
Historically, NOS have been classified into two distinct categories, constitutive 
(nNOS and ecNOS) and inducible [Nathan, et al, 1994]. Generally, nNOS and 
eNOS are produced constitutively in the cells, respectively, and require elevation 
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in intracellular Ca2+ and attendant activation of calmodulin to produce NO. These 
isoforms are regulated primarily by Ca2+ influx and generate low levels of NO for 
brief periods of time [Moncada, et ai, 2002. Bredt, et ah, 1992]. On the other 
hand, iNOS is an inducible form of NOS and needs to be induced by cytokines in 
essentially every cell type, and can generate locally high concentrations of NO for 
prolonged periods of time. The thesis dissects a very important aspect of eNOS in 












Figure 1.3 Nitric oxide synthesis by nitric oxide synthase (NOS) 
Nitric oxide (NO) produced from eNOS serves as an endogenous 
vasodilator, platelet inhibitor, antioxidant, and regulator of vascular endothelium 
by sustaining its anti-coagulant and antithrombogenic properties [Dudzinski, et 
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al., 2006]. Endothelial nitric oxide synthase (eNOS) is expressed not only in 
endothelial cells, but also in cardiac myocytes and blood platelets, where the 
enzyme subserves key roles in cardiovascular physiology [Dudzinski, et al., 
2005]. eNOS has also been reported to be expressed in diverse tissues including 
mast cells, renal epithelium, erythrocytes, and leukocytes. Because NO production 
must be carefully titrated to respond to diverse physiologic and pathophysiologic 
stimuli, eNOS is regulated by multiple interdependent control mechanisms and 
signaling pathways. 
1.3.1 Post-translational modifications to the eNOS 
1.3.1.1 Acylation 
In quiescent cells, eNOS is specifically targeted to small invaginations of 
the plasmalemma called caveolae. Caveolae are invaginated membrane micro-
domains defined by the presence of a scaffolding protein caveolin. The caveolae 
are enriched in cholesterol and sphingolipids [Govers, et al., 2001]. Caveolae 
sequester diverse receptors and signalling proteins from a variety of signal 
transduction pathways, including G protein coupled receptors, G proteins, growth 
factor receptors, Ca2+ regulatory proteins in microdomains, may serve to position 
eNOS to receive signals from these upstream signaling pathways and facilitate 
communication with downstream activators [Dudzinski, et al., 2006]. Localization 
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of eNOS to caveolae is dependent on irreversible, co-translational myristoylation 
of its N-terminal glycine (after removal of true N-terminal methionine) by N-
myristoyltransferase [Dudzinski, et al, 2006]. Myristoylation initially targets N-
Myr-eNOS to the cell membrane in general, where reversible post-translational 
palmitoylation of the Cys 15 and Cys 26 residues occurs by palmitoyltransferase 
[Shaul, et al, 2002]. Myristoylation and palmitoylation confer on eNOS three acyl 
anchors that anchor it firmly to the caveolar lipid bilayer. 
1.3.1.2 Intracellular Ca2+ levels and calmodulin binding 
Intra-cellular Ca2+ level are a critical determinant of eNOS activity 
because maximal catalytic function of eNOS requires calmodulin binding [Chen, 
et al, 2000]. Binding of calmodulin simultaneously disrupts the inhibitory 
caveolin-eNOS interaction [Michel, et al, 1997]. Numerous pathways converge 
on mobilization of intracellular Ca + transients to provide the most rapid 
mechanisms of eNOS activation via calmodulin. A diverse group of agonists, 
including bradykinin and acetylcholine [Goetz, et al, 1999], activate a G protein-
dependent signaling pathway that ultimately releases intra-cellular Ca2+ stores 
[Loscalzo, et al, 1995]. In this pathway, phospholipase C (PLC) cleaves 
membrane component phosphatidylinositol 4,5-triphosphate into diacylglycerol 
(an activator of protein kinase C) and inositol 1,4,5-triphosphate (IP3), which 
29 
binds to IP3 receptors that are found in high concentrations in caveolae and 
regulate intra-cellular Ca2+ through pleiotropic effects on ion channels [Fujimoto, 
etal, 1992]. 
1.3.1.3 Phosphorylation 
Phosphorylation and de-phosphorylation are also important regulatory 
factors on eNOS activity. Key serine and threonine residues in eNOS constitute 
regulatory loci: phosphorylations at Ser 1177 (primary sequence numbering 
corresponds to human eNOS), Ser 1179 (bovine), Ser 635, and Ser 617 are 
stimulatory while phosphorylations at Thr 495 and Ser 116 are inhibitory [Bauer, 
et al, 2003]. The activation of eNOS catalytic function by Ser 1177 
phosphorylation is due to inhibition of calmodulin dissociation from eNOS and 
also enhancement of the internal rate of eNOS electron transfer. Ser 1177 
phosphorylation is catalyzed by numerous kinases, including kinase Akt (protein 
kinase B) as well as the cyclic AMP-dependent protein kinase (PKA), AMP-
activated protein kinase (AMPK), PKG, and Ca2+/calmodulin dependent protein 
kinase II (CaM kinase II) [Fulton, et al., 2001] Phosphorylation at Ser 617, 
occurring downstream of either PKA or Akt, appears to sensitize eNOS to 
calmodulin binding [Michell, et al, 1997] and possibly modulate phosphorylation 
at other eNOS sites [Bauer, et al, 2003]. Phosphorylation at Ser 635 is responsive 
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to PKA and increases eNOS activity in response to PKA dependent agonists as 
well as basal stimuli like shear stress [Michell, et al, 2001] Phosphorylation at 
Thr 495, downstream of protein kinase C (PKC) and AMPK [Fulton, et al., 1999], 
attenuates the binding of calmodulin by eNOS; accordingly, agonist-mediated de-
phosphorylation of Thr 495, probably due to protein phosphatase 2A or protein 
phosphatase 1, enhances the interaction of eNOS and calmodulin. The 
phosphorylation state of Thr 495 helps adjust the product mix of eNOS output 
between superoxide and NO [Lin, et al., 2003]. Phosphorylation of eNOS at Ser 
116 inhibits enzyme activity, and de-phosphorylation of eNOS at this site is 
promoted by the eNOS agonist VEGF, but not by several other eNOS agonists 
[Kou, etal, 2002]. 
1.3.1.4 S-Nitrosylation 
Reversible 5-nitrosylation is recognized as an additional in vivo post-
translational control of eNOS activity [Erwin, et al, 2005]. Quiescent eNOS is 
inhibited by 5-nitrosylation at cysteine residues Cys 94 and Cys 99 that comprise a 
zinc-tetrathiolate cluster [Erwin, et al, 2005]. S-nitrosylation of eNOS leads to 
inhibition whereas de-nitrosylation stimulated by eNOS agonists is associated 
with increase in enzyme activity. Sub-cellular location also affects eNOS S-
nitrosylation and de-nitrosylation. Membrane targeting is required for S-
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nitrosylation owing to the facilitation of NO and gaseous reaction in the 
hydrophobic milieu of the membrane made of lipids. De-nitrosylation occurs 
intracellularly, facilitated by the cytosolic reducing environment and lack of 
proximity to membrane-bound enzymes that catalyze nitrosylation. 
1.3.2 Protein partners of eNOS in the caveolae 
1.3.2.1 Caveolin 
Caveolins are a 22 KDa proteins integrally linked to membrane owing to 
membrane-spanning domains and reversible post-translational triple C-terminal 
palmitoylation [Parat, et ah, 2001]. Caveolin-1 and caveolin-2 are ubiquitously 
expressed in endothelial cells; caveolin-3 is a muscle-specific isoform in 
cardiomyocytes and skeletal muscle [Rothberg, et ah, 1992]. Caveolin-1 and 
eNOS bind to each other by protein-protein interaction. Caveolin inhibits eNOS 
both by impeding the signalling of caveolae-targeted receptors that transducer 
eNOS-stimulatory signals as well as by sterically blocking the calmodulin binding 
site to eNOS [Michel, et ah, 1997]. 
1.3.2.2 Endoglin 
Endoglin (CD 105) is a 180 KDa glycoprotein highly expressed on 
endothelial cell membranes. It is enriched in caveolae and stabilizes eNOS by 
promoting its association with hsp90 [Toporsian, et ah, 2005]. 
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1.3.3 Signalling partners of eNOS 
1.3.3.1 PI3K/Akt 
Kinase Akt (protein kinase B) phosphorylates eNOS at Serll77. Kinase 
Akt is localized in the cytosol in inactive form and must translocates to the 
membrane for its own activation and eNOS phosphorylation [Gonzalez, et ah, 
2002]. It is controlled by the phosphoinositide-3-kinase (PDK)-dependent 
phosphorylation pathways and it appears PI3K recruits Akt to the membrane for 
phosphorylation [Vanhaesebroeck, et ah, 1997]. 
1.3.3.2 hsp90 
The role of heat shock protein 90 (hsp90), a chaperone involved in protein 
trafficking and folding, extends to agonist-dependent eNOS activation. eNOS 
becomes robustly associated with hsp90 as hsp90 undergoes reversible tyrosine 
phosphorylation in response to diverse eNOS agonists [Venema, et al, 1996]. 
Hsp90 binding stimulates eNOS activity by cooperatively enhancing the affinity 
of eNOS for binding calmodulin. Hsp90 also affects eNOS specific activity by 
means of effects on Akt. Hsp90 can bind both inactive and active Akt and is 
required for the interaction of Akt with eNOS [Garcia-Cardena, et al, 1998]. 
Furthermore, hsp90 maintains levels of phospho-Akt and thus Akt 
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phosphorylation activity by protecting PI3K from proteasomal degradation [Wei, 
et al, 2005] as well as inhibiting Akt deactivation by protein phosphatase 2A. 
Synergistic activation of eNOS can be seen following formation of a ternary 
complex containing hsp90, Akt, and calmodulin-bound eNOS [Takahashi, et al, 
2003]. Finally, NO itself may negatively modulate hsp90 by Snitrosylation of a 
cysteine residue that inhibits the hsp90 ATPase function and may disrupt eNOS-
hsp90 binding; this mechanism might provide negative feedback to regulate the 
amount of NO generation and/or facilitate cyclic eNOS activity [Martinez-Ruz, et 
al, 2005]. 
1.3.3.3 Phosphatases 
Depending on the site, dephosphorylation of eNOS could either activate 
the enzyme (e.g. Ser 116 or Thr 495), or attenuate enzyme activity (e.g. Ser 1177), 
perhaps returning NOS to basal activity after stimulatory phosphorylation. Several 
phosphatases, including serine-threonine protein phosphatase 1 (PP1), serine-
threonine protein phosphatase 2A (PP2A), and calcineurin participate in eNOS 
regulation. PP1 primarily de-phosphorylates Thr 495 and may activate eNOS 
[Fulton, et al, 2001]. A pathway involving the phosphatase calcineurin leads to 
de-phosphorylation of Ser 116 and to the activation of eNOS, while downstream 
of bradykinin calcineurin also de-phosphorylates Thr 495 [Harris, et al, 2005]. 
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PP2A functions as an overall negative regulator of eNOS due to its primary roles 
in de-phosphorylating phospho-Akt and de-phosphorylating Ser 1177 despite the 
fact that it can also de-phosphorylate Thr 495 [Wei, et al., 2006]. Possibly because 
of its high abundance and robust constitutive activity, the influence of PP2A on 
eNOS is regulated partly by the proteasome [Wei, et al, 2005]. Proteasomal 
inhibition causes PP2A ubiquitination and redistribution of PP2A from the cytosol 
to the membrane, thus leading to the association of PP2A with eNOS, and thereby 
reducing both phosphorylation of Akt and of eNOS at their respective stimulatory 




Figure 1.4 Post-translational activation of eNOS: In the top panel, eNOS 
under basal condition is less active. Under basal condition, eNOS is associated 
with caveolin, hsp90 and protein kinase C (PKC), which phoaphorylates it. eNOS 
association with caveolin and PKC renders it less active. Endothelial cell 
stimulation by various stimuli (bottom panel) activates eNOS catalysis [ie the 
conversion of L-arginine (L-Arg) to nitric oxide (NO)] through its association 
with calcium-activated calmodulin (CaM). More calcium fluxes in cytoplasm 
recruits more CaM to eNOS. The action of CaM may be facilitated by the 
recruitment of hsp90 to eNOS and from the dissociation of eNOS from caveolin. 
eNOS Ser 1177/1179 phosphorylation can be induced by both calcium-dependent 
and independent stimuli. Phosphorylation of these residues by Akt, protein kinase 
A (PKA) is associated with increased eNOS activity. 
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1.3.4 eNOS sub-cellular localization and trafficking 
In endothelial cells, eNOS appears to localize at peripheral region of the 
Golgi complex and cholesterol-rich microdomains of the plasma membrane (PM) 
such as caveolae. Co-translational N-myristoylation and posttranslational cysteine 
palmitoylation of eNOS determine its membrane targeting [Sessa, et ah, 2004]. It 
has been proposed that eNOS membrane localization may bring eNOS in close 
proximity to factors that are required for its proper function, such as L-arginine, 
BH4, CaM, and Akt which are less accessible to the Golgi-eNOS [Govers, et ah, 
2001]. 
1.3.4.1 NOSIP 
One eNOS-associated protein identified is the eNOS Interacting Protein 
(NOSIP), a 34 kDa protein that binds the carboxy-terminal of the eNOS 
oxygenase domain and appears to assist in translocation of eNOS from plasma 
membrane caveolae to intra-cellular membranes [Dedio, et ah, 2001]. Association 
of eNOS and NOSIP is inhibited by caveolin-1. 
1.3.4.2 NOSTRIN 
The second protein identified is the eNOS TRafficking INducer protein 
NOSTRIN, a 58 kDa protein of the PCH family (pombe cdc 15 homology) that is 
robustly expressed in endothelium and highly vascularised tissue [Schilling, et ah, 
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2006]. NOSTRIN shares the characteristic domain structure of PCH proteins, 
which includes an N terminal cdcl5 domain (consisting of an FCH region 
[Fes/CIP homology] followed by a coiled-coil structure) and C-terminal coiled 
coil and SH3 domains [Icking, et al, 2006]. The FCH region is sufficient to direct 
membrane targeting of NOSTRIN (to plasmalemma and peripheral vesicles), 
while FCH deletion mutants are found in the cytosol fraction [Icking, et al., 2006]. 
The NOSTRIN SH3 domain not only binds the oxygenase domain of eNOS. 
NOSTRIN interacts (via its C-terminus) with eNOS (oxygenase domain) and via 
its central domain with caveolin-1 (at its N-terminus). Caveolin-1 and NOSTRIN 
each enhance the binding of the other to eNOS on unique sites; accordingly, a 
ternary eNOS-NOSTRIN-caveolin-1 complex of unknown stoichiometry has 
been demonstrated in vivo; this ternary complex may localize at the plasma 
membrane [Schilling, et al, 2006]. 
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1.4 Endoplasmic Reticulum stress (ER stress) 
Endoplasmic Reticulum (ER) is a well designed site for the synthesis and 
folding of proteins. It is composed of protein chaperones, proteins that catalyze 
protein folding and sensors which detect the presence of misfolded or unfolded 
proteins. ER has several important functions involving glycosylation, formation of 
disulphide bonds, folding and assembly of newly synthesized proteins. All the 
proteins must undergo these processes properly in the ER before transit to the 
Golgi compartmen. A Quality Control which is sensitive surveillance mechanism 
exists in the ER that permits only properly folded proteins to exit the ER and reach 
other intracellular organelles and cell surface. Misfolded or unfolded proteins are 
either retained within the ER lumen in complex with molecular chaperones or are 
directed toward degradation through the 26S proteosome in a process called ER-
associated degradation (ERAD) or through autophagy. 
Accumulation of misfolded or unfolded proteins in ER disturbs ER 
function and cell survival can be threatened. Overload of these abnormal proteins 
in the ER triggers and ER stress response, termed as the unfolded protein response 
(UPR) [Marciniak, et ah, 2004]. The UPR is an intracellular signalling pathway 
that coordinates ER protein folding demand with protein-folding capacity and is 
essential to adapt to homeostatic alterations that cause protein misfolding. These 
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include changes in intraluminal Ca+ , altered glycosylation, and nutrient 
deprivations, pathogen infection, expression of folding-defective proteins and 
changes in redox status. ER serves as a cellular Ca2+ store and plays an important 
role in Ca2+ homeostasis by pumping Ca2+ into ER lumen via sarco-endoplasmic 
reticulum Ca2+ -ATPase (SERCA) and by releasing Ca2+ from the ER by inositol 
1,4,5- triphosphate (IP3) receptor and/or ryanodine receptor (RyR) [Oyadonaari, et 
al, 2004. Schroder, et al, 2005]. High concentration of Ca2+in ER is necessary for 
folding and disulphide bond formation of newly synthesized proteins and is 
required for the function of ER chaperones such as calreticulum, calnexin and 
protein disulphide isomerise (PDI). The ER also provides a oxidizing protein 
folding- environment that favors the formation of disulphide bond formation and 
results in the generation of reactive oxygen species (ROS) as a by-product of 
protein oxidation. 
When ER function is disturbed and unfolded or misfolded proteins 
accumulate in ER, the ER stress response pathway or the UPR is activated to 
restore normal ER functions. There are three ER stress sensors (Irel, ATF6 and 
PERK) on the ER membrane [Wang, et al, 1996]. In unstressed conditions, ER 
chaperone GRP78/BiP binds to the ER luminal domain of 3 ER stress sensors. 
When unfolded or misfolded proteins are accumulated in ER, GRP78/BiP 
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dissociates from ER stress sensors, and then binds to those abnormal proteins 
[Bertolotti, et al, 2000. Okamura, et al, 2000]. Dissociation of GRP78/BiP 
induces the activation of ER stress sensors. 
Four distinct ER stress response phases have been identified [Yoshida, et al, 
2003]- (1) Attenuation of translation (2) Induction of ER chaperones (3) 
Degradation of unfolded/misfolded proteins by ubiquitin-proteosome system (4) 
Apoptosis. Under ER stress condition, these 4 stages show a time-dependent 
transition [Yoshida, et al, 2002]. 
1.4.1 Attenuation of translation 
Under ER stress condition, PERK is activated by dimer formation and 
autophosphorylation. The activated PERK brings phosphorylation of eIF2a (a 
subunit of eukaryotic initiation factor 2) [Harding, et al, 2000]. The 
phosphorylated eIF2a blocks the binding of intiator Met-tRNA to ribosomes and 
so adenine-uracil-guanine (AUG) initiation codon recognition is reduced and the 
general translation is attenuated. However, translation of the transcription factor 
ATF4 is upregulated by eIF2a through induction of GADD34 (regulatory subunit 
of protein phosphatase) and activation of protein phosphatase 1 (PPlc) 
(Marciniak, et al., 2004). PPlc catalyzes the dephosphorylation of eIF2a. The first 
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stage of ER stress response is terminated by the re-binding of BiP to PERK and 
dephosphorylation of eIF2a. 
1.4.2 Induction of ER chaperones 
Protein folding in the ER is facilitated by ER chaperone proteins such as 
GRP78/BiP and GRP94 and by enzymes such as protein disulphide isomerase and 
peptidyl-prolyl isomerase [Schroder, et al., 2005]. Under ER stress conditions, the 
ER stress sensor ATF6 inactive form (p90ATF6) is transported to the Golgi and is 
activated by a 2-step cleavage by Site-1 protease (SIP) and Site-2 protease (S2P), 
then ATF6 active form (p50ATF6) is produced [Ye, et al., 2000]. The active 
p50ATF6 binds to the cis-acting ER stress response element (ERSE) of ER stress-
related genes such as GRP78/BiP and XBP1, then the transcription of those genes 
are activated [Yoshida, et al., 2003]. ER stress sensor Irel which on activation by 
dimer formation and autophosphorylation, splices out a small fragment of XBP1 
and activates it [Yoshida, et al., 2002. Calfon, et al, 2002. Lee, et al., 2002]. 
XBP-1 active form binds to ERSE to increase the transcription of ER stress-
related genes such as GRP78/BiP and XBP1 itself. Therefore, ATF6 and XBP1 
play the key role to enhance the folding activity in the second stage of ER stress 
response. 
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1.4.3 Degradation of unfolded/misfolded proteins by ubiquitin-proteosome 
system 
When the first two ER stress response phases are not able to rectify the 
unfolded /misfolded proteins, then the remainder of these are detected by the 
quality control system in ER, transported from the ER to cytosol and degraded by 
ERAD [Meusser, et al., 2005]. These proteins are retro-translocated to cytosol and 
degraded through the ubiquitin-proteasome system in cytosol [Gardner, et al., 
2001]. On ER stress, expression of ERAD-related molecules including EDEM is 
induced through active Irel and XBP1 signaling and ERAD activity is enhanced. 
1.4.4 Apoptosis 
When ER functions are severely impaired, apoptotic pathway is induced to 
eliminate the damaged cells [Oyadomari, et al., 2002]. There are 3 pathways 
involved in ER stress mediated apoptosis. The first is the transcriptional activation 
of the gene for C/EBP homologous protein (CHOP) [Zinszner, et al., 1998]. The 
second is the activation of the Irel-TRAF2-ASK1-MAP kinase pathway 
[Nishitoh, et al., 2002]. The third is activation of ER-associated caspase 12 
[Nakagawa, et al, 2000]. 
CHOP/GADD153 is expressed at low levels under physiological 
conditions but is strongly induced at the transcription level in response to ER 
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stress. There are at least 4 ER stress-responsive transcriptional enhancer elements 
(AARE1, AARE2, ERSE1 and ERSE2) in the transcriptional regulatory region of 
CHOP gene [Ubeda, et al., 2000]. The translational activation of ATF4 as a result 
of eIF2a is phosphorylation by activates PERK binds to the AARE1 and AARE2 
[Fewcett, et al., 1999]. XBP1 active form induced via the cooperation of ATF6 
and Irel pathway binds to ERSE and enhances the transcription of ER stress-
related genes including CHOP. Under ER stress conditions, the activity of CHOP 
is enhanced through the phosphorylation of Ser78 and Ser81 of CHOP protein by 
the p38 MAP kinase [Wang, et al., 1998]. Under ER stress condition, it is reported 
that p38 MAP kinase is activated through Irel-TRAF2-ASK1 signaling pathway. 
Therefore, it is speculated there may be a crosstalk between the CHOP pathway 
and ASK1 pathway. 
c-Jun N-terminal kinase (JNKs) and p38 MAP kinases are classified as 
stress-responsive MAP kinase family [Matsukawa, et al, 2004]. The apoptosis 
signal-regulating kinase 1 (ASK1) belongs to MAPKKK family and activates both 
the JNK and p38 pathways by phosphorylating and activating MAPKK family 
molecule SEK1/MKK7 and MKK3/MKK6/ASK1. ASK1 is activated by 
interaction with the TNF receptor-associated factor 2 (TRAF2). Under ER stress 
conditions, activated Irel recruits TRAF2 and then ASK1 directly binds to 
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TRAF2 and is activated [Nishitoh, et al, 2002]. The activation is ASK1 is also 
redox-dependent (Liu, et al., 2000). In unstressed condition, thioredoxin (Trx) 
directly binds to ASK1 and inhibits kinase activity. Trx is a ubiquitously 
expressed reduction/oxidation (redox)- regulatory protein and oxidized Trx cannot 
bind to ASK 1. 
Caspase 12 belongs to the ICE (Caspase-1) subfamily of caspase cysteine 
protease family [Oyadomari, et al., 2004]. ICE subfamily members function as 
activator of other caspases and cytokines by cleaving them. Caspase family 
molecules are produced as inactive pro-forms and are activated by cleavage when 
activating signals including apoptosis-inducing signals are transmitted. Pro-
caspase-12 is localized on the cytosolic side of the ER membrane and is activated 
by ER stress [Nakagawa, et al., 2000]. In ER stress condition, Ca2+ is released 
from ER to cytosol, then calpain, which is Ca2+ -dependent cysteine protease, is 
activated which activates caspase- 12 by cleavage [Nakagawa, et al, 2000]. The 
cytosolic caspase-7 is translocated from cytosol to ER in ER stress condition, and 
caspase-7 activates caspase-12 by cleavage [Rao, et al, 2001]. The activated Irel 
in ER stress conditions recruits TRAF2, which interacts with pro-capase-12 and 
promotes its clustering and activation [Yoneda, et al, 2001]. Activated caspase-12 
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cleaves procaspase-9 and activated caspase-9 activates procaspase-3 by cleavage. 
Activated caspase-3 activates apoptosis promoting molecules such as DNase. 
1.4.5 NO-Induced ER Stress 
NO- mediated apoptosis has been observed in diseases such as septic 
shock, autoimmune diseases, cerebral infarction and diabetes mellitus [Ignarro, et 
ah, 2000. Kroncke, et ah, 1991. Dimmeler, et ah, 1997]. NO has several cytotoxic 
effects including reactions with proteins and nucleic acids and causes apoptosis. 
NO induces DNA damage leading to cell death through induction of p53 and 
activation of poly (ADP-ribose) polymerase (PARP) (Messmer, et a.I, 2005). In 
unstressed condition, p53 is rapidly degraded, and the protein level of p53 within 
cells is low [Harris, et ah, 2001]. p53 is induced in response to DNA damage 
through suppression of rapid degradation, then the upregulated p53 either blocks 
cellular proliferation by cell cycle arrest at Gl stage or induces programmed cell 
death in the case of severe DNA damage. DNA damage also activates PARP, 
which results in depletion of NAD+ and ATP, subsequently, necrosis takes place. 
NO- induced apoptosis can be mediated by ER stress pathways. 
Calreticulin is a Ca2+ binding ER chaperone and maintainence of Ca2+ homeostasis 
in the ER is essential for protein folding because some of ER chaperones are Ca2+ 
dependent proteins [Schroder, et ah, 2005]. NO is reported to inhibit Ca2+ -
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ATPase activity of SERCA by tyrosine nitration [Xu, et al, 1999], or increase the 
activity of RyR through S-nitrosylation [Xu, et al, 1998]. Therefore, NO depletes 
ER Ca2+ either by inhibiting Ca2+ uptake from cytosol through SERCA or by 
activating Ca~+ release to cytosol through RyR. 
Another proposed mechanism for NO and ER stress- mediated apoptosis 
involves the effects of NO on mitochondria cytochrome c oxidase (complex IV). 
In physiological concentrations, NO bind to mitochondrial enzyme complex IV 
and inhibit it in a manner that is reversible and in competition with oxygen [Xu, et 
al, 2004]. Cytochrome c oxidase is the terminal enzyme of the mitochondrial 
respiratory chain. Therefore, increases in NO concentration can prevent the 
enzyme from using any available oxygen, prevent respiratory chain and can cause 
the production of ROS, changing the redox status of the cell [Xu, et al, 1998]. 
Protein folding process in the ER is highly redox-dependent, and can disturb ER 
function and activate ER stress pathway. As NO changes Ca2+ concentration in the 
ER, ATF6 is activated by proteolytic cleavage by the SIP and S2P proteases and 
the active ATF6 translocates to the nucleus to upregulate the ER stress- responsive 
genes. 
1.4.6 ER stress and oxidative stress in diseases 
1.4.6.1 Diabetes 
The type 2 diabetes is associated with a combination of insulin resistence 
in fat, muscle and liver and the failure of pancreatic P cells to increase insulin 
production [Saltiel, et al, 2001]. Oxidative damage is associated with the 
development of insulin resistance and diabetic state. Insulin signalling is also very 
sensitive to alterations in ER homeostasis and redox status. ER stress and 
oxidative stress as well as inflammatory cytokines and free fatty acids activate 
Irel, an ER stress sensor and which activates the JNK pathway. JNK then 
phosphorylates the Insulin Receptor Substrate-1 (IRS-1) on Ser307 which reduces 
insulin receptor-stimulated Tyr phosphorylation and insulin signalling. 
1.4.4.2 Neurodegenerative diseases 
Neurodegenerative diseases, such as Alzheimer disease (AD) and 
Parkinson disease (PD), represent a class associated with accumulation of 
abnormal protein aggregates in and around affected neurons. Oxidative stress and 
protein misfolding play critical roles in the pathogenesis of these diseases and are 
characterized by fibrillar aggregates composed of misfolded proteins. At the 
cellular level, neuronal death or apoptosis may be mediated by oxidative stress 
and ER stress or both. 
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1.4.6.3 Hyperhomocysteinemia and atherosclerosis 
Elevated plasma levels of homocysteine (Hey), sulphur-containing amino 
acids are linked to the development of ischemic heart disease, stroke and 
peripheral vascular disease. Hey induces protein misfolding in the ER and triggers 
the UPR [Huang, et al, 2006]. In causing ER stress Hey brings cholesterol 
dysregulation and triglyceride biosynthesis and leads to the accumulation of 
cholesterol in the cell [Werstuck, et al., 2001]. 
Atherosclerosis is caused by the abnormal deposition of cholesterol in the 
coronary arteries. Cholesterol accumulation in macrophages plays a critical role in 
the progression of atherosclerosis. Excess cholesterol must accumulate in specific 
pools within the cell to elicit cytotoxicity, by UPR signalling and caspase 




The sphingomyelin molecule is composed of a polar phosphorylcholine 
head group, an amide linked acyl chain, and a long chain sphingoid base. The 
polar head group of sphingomyelin is similar to the phosphorylcholine head group 
of phosphatidylcholines. The amide-linked acyl chains of sphingomyelin are 




Figure 1.5 Structure of sphingomyelin. Black is sphingosine, red is 
phosphorylcholine and blue is fatty acid. 
The subcellular distribution of sphingomyelin mass is confined to the 
plasma membrane (with most of it being in the exoleaflet). Sphingomyelin (SM) is 
synthesized by the reversible enzymatic transfer of phosphorylcholine group of 
phosphotidylcholine to ceramide, thus yielding Sphingomyelin and 
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Diacylglycerol. This reaction is catalyzed by Sphingomyelin synthase [Ullman, et 
al., 1974]. This event occurs mainly in the cis and trans Golgi network 
[Fulterman, et al., 1990]. The synthesized SM then reaches plasma membrane via 
vesicular flow. However, other subcellular sites have been described including 
endosomes and the nucleus [Kallen, et al, 1994]. An alternative route for SM 
biosynthesis has been reported involving CDP-choline as the phosphocholine 
donor [Diringer, et al, 1972]. Sphingomyelin synthase (SMS) which catalysis this 
reaction occurs in two isoforms in mammals SMS 1 and SMS 2 with SMS 1 
predominant in Golgi and SMS 2 in Plasma Membrane [Fulterman, et al, 1990 
and Kallen, et al., 1994]. The regulation of SMS depends on the levels of 
Ceramide and Diacylglycerol in the cell. Sphingomyelin is hydrolysed by 
sphingomyelinases (SMases) releasing ceramide and a cascade of bioactive lipids. 
These lipids include sphingosine and sphingosine-1-phosphate which have 
specific signalling capacity. Sphingomyelinases are present in various types of 
cells including cardiac myocytes, endothelial and vascular smooth muscle cells 
bringing about cell proliferation, cell death and contraction of cardiac and vascular 
myocytes. SMases have different isoforms according to their pH optima- alkaline, 
acid and neutral, localization and cation dependence. These isoforms are- Alkaline 
SMase, confined to the intertinal mucosa, bile and liver. Acid SMases (ASMases) 
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and neutral SMases (NSMases), however are crucially involved in cardiovascular 
physiology and pathophysiology. 
1.5.2 Acid sphingomyelinase 
Acid sphingomyelinase is further classified into two on the basis of their 
localization in the cell- Lysosomal sphingomyelinase (L-SMase) and secretory 
sphingomyelinase (A-SMase). 
1.5.2.1 Lysosomal Acid sphingomyelinase 
Lysosomal ASMase is 70 kDa glycoprotein with oligosaccharide side 
chains containing mannose-6-phosphate residues, typical of lysosomal proteins. 
It's in vitro pH optimum is between 4.5 and 5, and SM accumulation in the 
lysosomes of Niemann Pick Deficient (NPD) patients further supports its 
classification as a lysosomal protein [Fowler, et ah, 1969]. L-SMase requires Zn2+ 
for activity and is tightly bound to Zn2+. 
1.5.2.2 Secretory Acid sphingomyelinase 
S-ASMase contains complex N-linked oligosaccharides. Its activity is 
highly dependent on the availability of Zn2+ and requires exogenous Zn2+ for its 
optimum activity [Tabas, et ai, 1999]. 
1.5.3 Lysosomal Acid sphingomyelinase and vascular tone 
In human lymphocytes, TNF receptor superfamily receptors triggers L-
ASMase translocation from lysosomes to the extracellular surface of the cell 
membrane. The translocated L-ASMase localizes to sphingolipid-rich 
membrane lipid rafts and releases extracellularly orientated ceramide. This allows 
the formation of larger ceramide-enriched platforms, which serve to cluster the 
receptors determining the initiation of apoptosis signalling [Gulbins, et al, 2003]. 
The mechanism involves phosphorylation of L-ASMase by PKC5 [Zeidan, et al., 
2008]. L-ASMase dependent formation of ceramide-enriched lipid macrodomains 
in VSMCs and EC contributes to FasL-induced impairment of the vasodilator 
response [Jin, et al., 2008. Zhang, et ah, 2007] and muscarinic-1 receptor-
mediated coronary artery constriction [Jia, et al, 2008] which are both major 
aggravating factors in atherosclerosis. 
1.5.4 Secretory Acid sphingomyelinase in atherosclerosis 
Both proliferation and death of VSMCs contribute to the progression of 
the atherosclerotic lesions. The sphingomyelin/ceramide pathway in 
atherogenesis, through a mitogenic effect on VSMCs. Endothelial cells, which 
cover the atherosclerotic lesions, secrete S-ASMase. Enzyme secretion is 
enhanced by atherogenic pro-inflammatory cytokines [Marathe, et al, 1998]. 
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Secreted ASMase hydrolyses SM to ceramide on the surface of atherogenic 
lipoprotein particles, even at neutral pH [Schissel, et al, 1998]. The resulting 
increase in lipoprotein ceramide promotes fusion and subendothelial aggregation 
of the lipoprotein particles, increasing their affinity for arterial wall proteoglycans 
and leading to foam cell formation [Tabas, et al, 2007]. Also, oxidized 
phospholipids that are found in atherosclerotic lesions may promote VSMC death 
via ASMase activation [Loidl, et al, 2003]. 
1.5.5 Secretory Acid sphingomyelinase in heart failure 
In addition to neuro-hormonal activation, inflammation and oxidative 
stress are key mediators in chronic heart failure (HF) progression [Keith, et al, 
1998. Castro, et al, 2002. McMurray, et al, 1993] and severity [Mallat, et al, 
1998]. The ability of pro-inflammatory cytokines to trigger S-ASMase secretion 
from ECs [Marathe, et al, 1998] combined with the stimulatory effect of reactive 
oxygen species (ROS) on enzyme activity [Grammatikos, et al, 2007] are 
possible mechanisms explaining the increase in plasma S-ASMase activity in 
patients with HF [Doehner, et al, 2007]. 
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1.5.6 Neutral Sphingomyelinase 
Neutral Sphingomyelinase (NSMase) has 3 isoforms- two of them are 
Mg2+ dependent that are termed as NSMase 1 and NSMase2 and the third form is 
Mg2+ independent (NSMase3). 
1.5.6.1 Neutral, Mg2+ -dependent sphingomyelinase 
Neutral Mg -dependent sphingomyelinase (~92kDa) is integral 
membrane protein. The enzyme has pH optima near pH 7.0 and requires mM 
amounts of Mg2+ and Mn2+ for activity. Mg2+ -NSMase has several locations in the 
cell, NSMasel is localized in the nucleus, ER and Golgi [Mizutani, et al., 2001. 
Tomiuk, et al, 2000] and NSMase2 in the inner leaflet of the plasma membrane 
[Tani, et al, 2007]. 
1.5.6.2 Neutral, Mg2+ -independent sphingomyelinase 
This enzyme is termed as NSMase3 and is present in the cytosol. It is a 
small protein of 53 KDa molecular weight. 
1.5.7 Neutral sphingomyelinase signalling pathways and cardiovascular 
dysfunction 
In isolated cardiac myocytes, NSMase mediates apoptosis elicited by TNF-
a [Krown, et al, 1996. Oral, et al, 1997] or IL-ip [Radin, et al, 2008]. 
Glutathione inactivates NSMase and lower levels of glutathione are required for 
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the binding of NSMase to TNFa receptor [Defer, et al, 2007]. In cultured VSMC, 
apolipoprotein C-l (apoC-l)-enriched high-density lipoproteins (HDLs) stimulate 
NSMase, triggering an apoptotic response via the release of cytochrome c from 
mitochondria and caspase-3 activation [Kolmakova, et al, 2004]. Apoptosis of 
VSMCs is a critical event in the rupture of atherosclerotic plaque, leading to 
thrombosis, myocardial infarction and possible death. Oxidized low density 
lipoproteins (oxLDLs) and TNF-a also stimulate NSMase in VSMCs. However, 
these stimuli do not trigger apoptosis, but instead contribute to VSMC 
proliferation resulting from the metabolism of ceramide into Sphingosine-1-
phosphate (SIP) and the downstream activation of ERK1/2 MAPKinases [Auge, 
et al. 2002]. In cultured VSMCs, the NSMase2 isoform is involved in the ROS 
and oxLDL induced proliferation and the process of NSMase2 activation that 
relies on a proteolytic cascade involving furin/membrane type 1-matrix 
metalloprotease (MTl-MPP)/MMP-2 proteases [Coatrieux, et al, 1997]. Through 
NSMase activation, oxLDLs induce cultured VSMC proliferation which in situ 
contributes to the formation and progession of atherosclerotic lesions. OxLDLs 
are present in both animal and human atherosclerotic lesions and trigger the 
progression of atherosclerosis and plaque rupture. 
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Objectives of the study: 
Objective 1. How increased plasma membrane cholesterol content can 
affect nitric oxide diffusion, dynamics and signalling? 
To achieve this objective we carried out the study by having the 
knowledge about the basic property of nitric oxide that it tends to partition in the 
hydrophobic milieu in the biological membrane. This property of nitric oxide led 
us to think that if nitric oxide favors hydrophobicity then what would be the 
consequences on nitric oxide diffusion from plasma membrane and its subsequent 
intracellular signalling brought by cGMP activation and VASP (Ser239) 
phosphorylation, if this hydrophobicity was further increased in the form of more 
cholesterol content in the plasma membrane. From this study, we drew the 
conclusion that nitric oxide diffusion from plasma membrane, cGMP response and 
VASP (Ser239) phosphorylation was significantly reduced under conditions where 
there was more cholesterol in the plasma membrane. This important finding can 
serve as a plateform for the studies which involve cancer, neurodegeneration and 
cardiovascular disorders where the bioavailability of nitric oxide is severely 
decreased leading to adverse consequences. 
Objective 2. (i) Can endoplasmic reticulum stress (ER stress) lead to 
increase in plasma membrane cholesterol content? 
(ii) How ER stress causes increase in plasma membrane cholesterol content? 
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(iii) Whether increase in plasma membrane cholesterol can influence nitric 
oxide production/diffusion and eNOS localization in the endothelial cells? 
The study was performed by bearing the rationale that if ER stress 
upregulates genes for cholesterol synthesis leading to increase in the accumulation 
of intracellular cholesterol then can ER stress also give rise to plasma membrane 
cholesterol, as plasma membrane not only holds -90% cellular cholesterol but also 
is the site from where influx and efflux of cholesterol takes place. The result of 
this study showed that there was a huge increase in cholesterol content in the 
plasma membrane under ER stress condition. To investigate as to how this 
dysregulation in plasma membrane cholesterol is brought through, we found that 
neutral sphingomyelinase2, a plasma membrane resident enzyme responsible for 
maintaining cholesterol balance in plasma membrane is inactivated by S-
nitrosation of Cys thiols and nitration of Tyr residues under ER stress. Part (iii) of 
Objective 2 was carried out as a follow up of Objective 1 and here we wanted to 
determine nitric oxide release under increased plasma membrane cholesterol 
brought by ER stress. We found that there was a gradual decline in nitric oxide 
release as the ER stress was prolonged. Then we wanted to investigate the issue of 
eNOS localization in the Golgi, where eNOS is known to produce less nitric oxide 
and the studies performed till the time showed that under ER stress condition, 
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intracellular vesicular transport is obstructed with proteins getting trapped in the 
ER and Golgi. With the available knowledge we hypothesized that could the 
gradual decline in nitric oxide production as a result of ER stress be due to eNOS 
getting trapped in the Golgi. And consistent to our expectation we determined that 
there was some eNOS getting localized in the Golgi under ER stress. 
The study can give important insights in the development of endothelial 
dysfunction, where hypercholesterolemia and decrease in bioavailability of nitric 




Cloning and characterization of Perfringolysin O-
Domain 4 (PFO-D4) with cholesterol on 
Bilayer Lipid Membrane (BLM) 
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2.1 Introduction 
Thiol-activated cytolysins comprise a large family of bacterial protein 
toxins that are secreted by Gram-positive bacteria [Alouf, et al., 1991.]. They 
share 40-70% homology in their amino acid sequences and have common 
functions, cholesterol binding and pore-formation through oligomerization on 
plasma membrane [Tweten et al., 1988. Shimuzu, et al., 1991. Kehoe, et al. 
,1987]. Perfringolysin O is a 472 amino acid residues cytolysin produced by 
Clostridium perfringens type A bacteria. Its cytolytic activity is mainly brought 
about by 4 steps which occur in sequential order: 1. Binding to plasma membrane 
cholesterol 2. Insertion into the membrane 3. Oligomerization 4. Pore formation 
[Shatursky, et al., 1999]. The three dimensional structure of theta-toxin elucidated 
by X-ray diffraction studies revealed that it is a P-sheet rich, elongated rod-shaped 
molecule and consists of four discontinuous domains [Sugahara, et al., 1996]. 
Domain 4 or the C-terminal domain, is an autonomous structure comprising of 
amino acid residues 363-472. The Domain 4 has a highly conserved 
undecapeptide sequence ECTGLAWEWWR (amino acid residues 430-440) 
having a single cysteine and PFO has only one cysteine in the whole protein. This 
single cysteine is essential for the oligomerization of monomers of theta-toxin to 
form a prepore assembly onto the plasma membrane followed by pore formation 
61 
[Hotze, et al., 2001]. Recently, there was a report suggesting that the three short 
hydrophobic loops (L1-L3) at the tip of Domain 4 of the PFO are responsible to 
anchor the molecule onto the cholesterol-rich membrane [Soltani, et al., 2007]. 
There are several different kinds of probes available for visualizing 
cellular cholesterol such as filipin, NBD-cholesterol, dehydroergosterol (DHE) 
etc. But all of these probes suffer from limitations that they can indiscriminately 
target cholesteryl esters, can quickly photobleach, can permeabilize the cell and 
cannot differentiate between the intracellular cholesterol pool and plasma 
membrane cholesterol where -90% of the cellular cholesterol resides [Lange, et 
al., 2000]. The purpose of the present study was to generate a cholesterol probe 
which can target exclusively plasma membrane cholesterol and for this we 
exploited the cholesterol binding property of the Domain 4 of PFO. Although 
there has been several studies done to characterize the binding capacity of 
PFO/PFO-D4 with cholesterol by using large unilamellar liposomes, intact cells or 
isolated cholesterol-rich microdomains [Alouf, et al., 1984. Ohno-Iwashita, et al, 
1988. Ohno-Iwashita, et al., 1990], but all these studies have limitations in that 
these studies could not be utilized to estimate cholesterol levels in the membrane. 
In the present study, we have used a bilayer lipid membrane chamber and 
fluorescence microscopy to make a bilayer membrane over a 1 mm hole using a 
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canonical lipid raft mixture [Fidorra, et ah, 2006. Nicolini, et al., 2006. Veatch, et 
al., 2003]. By performing titration with increasing [PFO-D4-GFP] on bilayer lipid 
membrane made with varying mol% of cholesterol we obtained a saturation curve. 
The dissociation constant (KD) of PFO-D4 was obtained from the saturation curve 
at the point of saturation and the KD values clearly showed the PFO-D4 
specifically binds to cholesterol and show a stronger binding with higher mol% of 
cholesterol in the membrane. 
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2.2 Materials and equipment 
2.2.1 Materials 
Tris-HCl, NaCl, Imidazole, Lysozyme, DNasel, Phenylmethanesulphonylfluoride 
(PMSF), Ampicillin, Isopropyl f$-D-l-thiogalactopyranoside (IPTG) and 1-
palmitoyl 2- oleyl phosphotidylcholine (POPC) was purchased from Sigma-
Aldrich Canada (Oakville, ON). Sphingomyelin (chicken egg derived) and 
cholesterol (plant derived) was purchased from Avanti Polar lipids Inc. (Alabaster, 
AL, USA). Methonal and chloroform was purchased from Merck KGaA 
(Darmstadt, Germany). Restriction enzymes and Phusion™ High-Fidelity DNA 
Polymerase were purchased from New England Biolabs (Pickering, ON, Canada). 
Plasmid GFPuv was purchased from Clontech (Mountain View, CA, USA). 
pTrcHisB vector was purchased from Invitrogen (Carlsbad, CA, USA). XL-1 Blue 
supercompetent cells were purchased from Stratagene (Cedar Creek, TX, USA). 
2.2.2 Equipment 
Northern Eclipse 6.0 Imaging Software; Empix Imaging Inc., Mississauga, ON. 
Zeiss Axiovert 200 Inverted Fluorescence Microscope, Empix Imaging Inc., 
Mississauga, ON. 
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Agilent 8453 UV-VIS Spectrophotometer, Agilent Technologies, Canada, Inc, 
Mississauga, ON 
Mettler AJ1000 Balance; Mettler, Toledo Canada, Mississauga, ON 
Orion Model 420A pH Meter, Thermo Electron Corp. Canada, Burlington, ON 
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2.3 Methods 
2.3.1 Cloning of truncated PFO: 
To make truncated PFO, we used the plasmid pRTIO (a generous gift from Dr. 
Rodney Tweten) containing the perfringolysin O gene (pfoA) in the pTrc HisC 
vector. The pRTIO plasmid was restriction digested between BamHI and Bglll 
restriction sites and the DNA fragment from Phe252-Asn50o with the cohesive ends 
was treated with mung bean nuclease at 37 °C for 20 min to generate blunt ends. 
The blunt ended DNA fragment was then self ligated and the vector was 
transformed into XL-1 blue supercompetent cells for amplification and sequenced. 
2.3.2 Cloning of PFO-D4 in pTrcHisB vector: 
The pRTIO plasmid containing the perfringolysin O gene (pfoA) was used 
to construct the pfoA derivative D4 encoding the C-terminal region of the toxin. 
The DNA fragment containing the D4 (Lys39i-Asn5oo) encoding region was PCR 
amplified using pRTIO plasmid as the template and ligated into the pTrcHisB 
expression vector, inserting it between the BamHI and KpNl restriction sites on 
the 3'-end of the sequence encoding the His tag site. The polymerase chain 
reaction primers used were as follows: Forward primer, 5'-
CCCGGATCCGTCTACAGAGTATTCTAAGG-3'; reverse primer, 5'-
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CCCGGTACCGGATTGTAAGTAATACTAGATCC-3'. The cloned vector was 
transformed into XL-1 blue supercompetent cells for amplication and sequenced. 
2.3.3 Cloning of PFO-D4-pTrcHisB plasmid with GFP: 
The PFO-D4-pTrcHisB plasmid was used to insert the GFP gene. The GFP 
insert was isolated from the pGFP vector by restriction digesting the vector 
between KpNl and EcoRl sites and ligated between these sites in the PFO-D4-
pTrcHisB vector, thus inserting it at the 3'-end of the PFO-D4-pTrcHisB vector. 
The cloned vector was transformed into the XI-1 blue supercompetent cells and 
sequenced. 
2.3.4 Transformation and protein expression of PFO-D4-GFP in XL-1 Blue 
supercompetent cells: 
A 50ul aliquot of XL-1 blue supercompetent cells was added to prechilled 
polypropylene round bottom tubes. Approximately, 2|j,l of PFO-D4-GFP plasmid 
was added to the cells and the tubes and swirled gently. The mixture was 
incubated on ice for 30 min. Following incubation the cells were heat shocked in 
42 ° C water bath for 45 s and incubated on ice for 2 min. Approximately, 200ul of 
the preheated SOC medium was added to the cells and the cells were incubated at 
37 ° C for 1 h under shaking at 225 rpm. The mixture was then plated on LB agar 
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plates containing 50u,g/ml ampicillin and incubated at 37 ° C for 16-18 h. A single 
colony from the plate was streaked into 50ml of Terrific Broth (TB) containing 
50|xg/ml ampicillin and grown overnight at 37 C under 250 rpm. The overnight 
grown culture was transferred into 1L TB+Amp (50(xg/ml) and incubated for 6 h 
at 37 ° C under 250 rpm with an optical density of 0.6. To induce PFO-D4-GFP 
protein expression ImM IPTG in 50% glycerol was added to the cells and again 
incubated for 6 h at 37 ° C under 250 rpm. 
2.3.5 Purification and quantification of PFO-D4-GFP protein: 
The induced culture was centrifuged at 5000Xg for 30 min and the pellet 
was resuspended in 20 ml of the lysis buffer (100 mM Tris-HCl, 250 mM NaCl 
with 30 mM Imidazole pH 8.0, lOOug/ml lysozyme, 50ug/ml DNasel, 2mM 
PMSF and 1% Triton X-100). The suspension was incubated on ice for 30 min, 
sonicated at level 4 for 8 pulses (20 s each pulse) and then centrifuged at 17000Xg 
for 30 min at 4° C. The clear supernatant was added to the nickel column, which 
was equilibrated with 10 mM Imidazole buffer (100 mM Tris-HCl, 250 mM NaCl 
pH 8.0). After loading the sample, the column was again equilibrated with 3 
column volumes of 10 mM Imidazole buffer. The protein was eluted with 2 
column volumes of 300 mM Imidazole buffer (lOOmM Tris-HCl, 250 rpm NaCl 
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pH 8.0). Imidazole was removed and the buffer was exchanged with Hepes buffer 
pH 7.4 in the eluted protein using Amicon centrifugal filters. The protein was 
aliquoted into 50ul and stored at -80 C for future use. The quantification of the 
purified protein was done by measuring optical density at 280 nm with PFO-D4-
GFP having and extinction coefficient of 59740 M-'cm-1. 
2.3.6 Bilayer Lipid Membrane (BLM) setup: 
To access the cholesterol specificity of PFO-D4-GFP we made a bilayer 
membrane (BLM) setup that had a teflon film with a 1mm diameter hole on which 
the artificial lipid membrane was made. The teflon film rested on a trough filled 
with Hepes buffer pH 7.0 (aqueous phase) maintained at 37 °C, the lipids used to 
make the bilayer were dissolved in organic solution and that constituted the 
organic phase and with and after overlay of PFO-D4-GFP in Hepes buffer pH 7.0 
there was an organic phase in the middle with aqueous milieu on top and bottom 
making a lipid bilayer. 
2.3.7 Cholesterol specificity of PFO-D4-GFP on BLM: 
The lipids in the organic phase consisting of POPC, 10 mol% 
sphingomyelin and varying mol% of cholesterol (5 mol%, 10 mol%, 20 mol%, 30 
mol% and 40 mol%) keeping the number of moles of POPC constant was 
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dissolved in 2:1 chloroform:methanol was used to make the membrane. A small 
aliquot of 2ul of the lipid mixture was added on top of 1mm hole in the Teflon 
film, held at 37 °C. After the organic solvents were evaporated, lul of PFO-D4-
GFP with different concentrations was laid over the dried lipid membrane and 
incubated for 15 min, followed by washing with Hepes buffer pH 7.0. Thereafter, 
the bilayer lipid membrane was imaged in the fluorescent microscope to see the 
binding of PFO-D4-GFP on cholesterol in the membrane interpreted as means of 
average fluorescence of PFO-D4-GFP with excitation/emission at 390 nm/510 
nm. 
2.3.8 Cholesterol specificity of PFO-D4-GFP with Methyl p-cyclodextrin 
treatment on the BLM: 
A lipid raft mixture with POPC:sphingomyelin and 20 mol% of cholesterol 
was made as described above. Thereafter, the membrane was treated with different 
concentrations of methyl-P-cyclodextrin dissolved in Hepes buffer pH 7.0 (OmM, 
2.5mM, 5mM and lOmM) and then probed for cholesterol with 720nM PFO-D4-
GFP. The bilayer lipid membrane was imaged in the fluorescent microscope to see 
the binding of PFO-D4-GFP with cholesterol in the membrane, interpreted as 
means of average fluorescence of PFO-D4-GFP. 
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2.4 Results 
Lipid raft mixture consisting of POPC:sphingomyelin:cholesterol with 
following mol%- 85:9:5 mol%, 84:8:10 mol%, 30:3:20 mol%, 22.8:2.3:30 mol%, 
18:2:40 mol% was used to make the horizontal bilayer membrane (BLM) 
designed for an inverted microscope. The number of moles of POPC was kept 
constant and the mol% for each lipid was calculated by taking the total number of 
moles of the lipids. As mentioned above, that PFO contains one cysteine residue at 
amino acid position 431 residing in D4 of the PFO and this cysteine is essential 
for the oligomerization of monomers to form prepore complex on the plasma 
membrane, the PFO plasmid which was a generous gift to us from Dr. Rodney 
Tweten was mutated by replacing Cys43i with Ala at this position keeping the total 
number of amino acids in the protein same as 472 residues. In order to test the 
cholesterol specificity of PFO-D4-GFP, the above mentioned BLM mixtures were 
exposed to increasing concentration of PFO-D4-GFP construct. As can be seen 
from Fig. 2.1.1 (a-e) that there was an increase in the fluorescence when 
increasing concentration of PFO-D4-GFP was added to the BLM mixtures of each 
ratios and at a certain concentration of PFO-D4-GFP there was no further increase 
in the fluorescence Fig 2.1.1 (a-e) and a plateau was reached with further addition 
of higher PFO-D4-GFP concentration thus generating a saturation curve Fig. 
71 
2.1.2. This showed the fluorescence increase, as a function of concentration of 
PFO-D4-GFP, displayed saturation behaviour. The specificity of PFO-D4-GFP for 
cholesterol, on the lipid raft mixtures with varying mol% of cholesterol (5 mol%, 
10 mol%, 20 mol%, 30 mol% and 40 mol%) was made and used to determine its 
apparent dissociation constant KD and any change in KD values with increasing 
mol% of cholesterol in the BLM. As the fluorescence increase and PFO-D4-GFP 
concentration showed saturation behaviour, the apparent KD of the various 
sphingomyelin to cholesterol mixtures for PFO-D4-GFP estimated from the fit of 
the data to a saturation function, indicated that as the mol% of cholesterol 
increased the apparent KD decreased. And as can be seen from Fig.2.1.1 (a-e) and 
Fig 2.1.2 as the mol% of cholesterol was increased the plateau with the 
fluorescence was reached at a lower concentration of PFO-D4-GFP and thus 
displays a decrease in the KD values (5 mol% KD= 2.3UM, 10 mol% KD= 1.02uM, 
20 mol% KD= 0 .52UM, 30 mol% KD= 0.43uM, 40 mol% KD= 0.16uM) Fig. 2.1.2 
inset. The cholesterol specificity of PFO-D4-GFP was further verified in another 
way where methyl-p- cyclodextrin was used to extract cholesterol from the raft 
mixture on the model membrane. Methyl-p-cyclodextrin at concentrations (OmM, 
2.5mM, 5mM and lOmM) was incubated with the model membrane prior to the 
addition of PFO-D4-GFP and the fluorescence was measured. Fig 2.2 (a) shows a 
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decrease in the fluorescence as the concentration of methyl-P-cyclodextrin was 
increased thus showing that with less cholesterol PFO-D4-GFP displays a less 
binding characteristic in the model membrane. 
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2.5 Discussion 
Lipid rafts are microdomains on the plasma membrane which are formed 
of sphingolipid (mainly sphingomyelin) and cholesterol and phospholipids and 
scattered on the plasma membrane. We used raft mixtures with varying mol% of 
cholesterol to determine the binding specificity of PFO-D4-GFP to cholesterol and 
our data clearly indicate that PFO-D4-GFP binds specifically to cholesterol and 
prefers higher cholesterol concentrations for tighter binding. 
Our study with the raft mixture showed that PFO-D4 requires more 
cholesterol to strongly bind to the membrane. As can be seen from Fig.2.1.1(a-e) 
and Fig. 2.1.2 there is a decrease in the KD values with increase in the mol% of 
cholesterol. Most of the studies performed on PFO till date on its dynamics of 
cholesterol binding are with erythrocytes and erythrocytes have huge amount of 
cholesterol in plasma membrane. The present and the previous studies converge at 
the same point that PFO binding is specific to cholesterol on the plasma 
membrane and the present study shows the cholesterol specificity of PFO in terms 
of its dissociation constant, KD. The relationship between apparent KD was non-
linear and could be fit by the equation apparent KD= 11.14/ [Cholesterol mol%] 
Fig 2.2 (f) inset. Rafts contain a 1:1 mixture of sphingomyelin to cholesterol. The 
fact that the apparent KD decreased or the interaction between PFO and cholesterol 
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increased at the point when the cholesterol to sphingomyelin ratio increased above 
one i.e. (-10 mol %) supports the recent findings that PFO-D4 interacts with free 
cholesterol in the plasma membrane [Flanagan, et al. 2009]. Furthermore, these 
results suggested that we could use the equation obtained from the model 
membrane studies to estimate free cholesterol concentrations in the cell 
membranes by simply performing a PFO-D4-GFP titration. 
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[PF0-D4] 0 80 160 32ft W 720 110 1140 2280 $840 i?S0 7SS0 
(nil) 
Figure 2.1.1 Pictures displaying the titration of cholesterol in bilayer lipid 
membrane (BLM) with PFO-D4-GFP. BLM made of POPC: sphingomyelin: 
cholesterol with varying mol% of cholesterol (5mol%, 10mol%, 20mol%, 
30mol%, 40mol%) where the mol% of POPC and sphingmyelin were kept 
constant and the mol% for each lipid were calculated by taking the total number of 
moles of the lipids. 
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Figure 2.1.2 Titration of cholesterol in bilayer lipid membrane (BLM) with 
PFO-D4-GFP. Bilayer lipid membrane chamber designed was used to make 
horizontal bilayer membrane with the following POPC:Sphingomyelin:cholesterol 
mol% ratios- 85:9:5 mol% u , 84:8:10 mol% ®, 30:3:20 mol% a, 22.8:2.3:30 
mol% v , 18:2:40 mol% B . The number of moles of POPC and Sphingomyelin 
was kept constant and the mol% was calculated by taking the total number of 
moles of the lipids. Various [PDO-D4-GFP] were incubated with the bilayer 
membrane at 37° C in Hepes buffer pH7.4 and the apparent dissociation constant, 
KDwas determined at the saturation limit of [PFO-D4-GFP]. The inset shows the 
apparent KD of PFO-D4-GFP as a function of [cholesterol] (mol%) in the bilayer 
membrane. The error bars show S.D. (n=5). 
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PFO-D4-GFP binding on BLM after treatment with 
Methyl p cyclodextrin 
o 
o 4 6 6 
MpCDConc|mM) 
10 12 
Figure 2.2 Cholesterol specificity of PFO-D4-GFP on BLM cholesterol 
after extraction from methyl-p-cyclodextrin. The cholesterol extraction from 
the raft mixture with POPC: sphingomyelin: cholesterol with the ratio 30:3:20 
mol%, by methy-p-cyclodextrin extraction and incubated with 720nM of PFO-D4-
GFP. The plot depicts the decrease in average fluorescence of PFO-D4-GFP. 
Part III 
Chapter 3 
Plasma membrane cholesterol content affects nitric 
oxide diffusion, dynamics and signalling 
Published as original in The Journal of Biological Chemistry, (2008) 283,18513-21. 
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3.1 Introduction 
Nitric oxide (NO) is a small, gaseous free radical and is produced by nitric 
oxide synthase. Several regulatory factors at the level of nitric oxide synthase 
catalysis influence the rate of NO generation. The lifetime of NO molecules is 
governed by their relative abundance in relation to other radicals [Issner, et al, 
1997. Lima, et al. 2003], transition metal centers [Chiang, et al, 2006. Mason, et 
al, 2006] and oxygen (02) [Caccia, et al, 1999. Lewis, et al, 1994]. Also, NO 
being a very small molecule, its diffusional path of NO from the point of origin is 
affected by its hydrophobic solubility [Wood, et al, 1994. Philippides, et al, 
2000], resulting in an enrichment of NO in biological membranes in relation to the 
aqueous milieu. In the present work, the hypothesis that the cells may utilize 
plasma membrane cholesterol to further orchestrate spatial heterogeneity in NO 
biological signalling activity was tested. 
Cholesterol, a major lipid component of the plasma membrane in 
eukaryotic cells, plays an essential role in maintaining membrane fluidity and 
architecture [Hao, et al, 2001. Rukmini, et al, 2001]. Cells tightly control the 
ratio of cholesterol and phospholipids in plasma membrane, segregate with 
sphingolipids and proteins to form distinct lipid raft complexes that are ordered 
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platforms for communicating signals into and out of the cells [Simons, et ah, 
1997]. Dysregulation of cholesterol synthesis and transport acts as a contributing 
factor to pathophysiological changes [Mason, et ai, 2003. Chen, et al., 1995], 
which are of particular importance in cardiovascular disease, chronic 
inflammation and lipid disorders such as Niemann-pick disease. The influence of 
cholesterol on NO diffusion and signalling dynamics was seen by soluble guanylyl 
cyclase (cGCs) activation and VASP phosphorylation (Ser 239). These data show 
that one effect of plasma membrane cholesterol content on modulation of the level 
and type of NO signalling; pathological alterations in levels and distribution of 
cellular cholesterol may contribute a mechanism of errant NO signalling. 
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3.2 Materials and Equipment 
3.2.1 Materials 
Tris-HCl, EDTA, PMSF, L-NMMA, DMEM were purchased from Sigma Canada 
(Oakville, ON). DEA/NO was purchased from Calbiochem (Los Angeles, CA, 
USA) Amplex Red cholesterol assay kit was obtained from Invitrogen (Carlsbad, 
CA, USA). The cGMP enzyme immunoassay kit was purchased from Amersham 
Biosciences (Piscataway, NJ, USA). Normal human fibroblasts (HFF-1) were 
obtained from ATCC (Manasass, VA, USA). NPC1 fibroblasts (GM17923) were 
obtained from the Coriell Cell Repository (Camden, NJ, USA). 
3.2.2 Equipment 
Agilent 8453 UV-VIS Spectrophotometer, Agilent Technologies, Canada, Inc, 
Mississauga, ON 
Mettler AJ1000 Balance; Mettler, Toledo Canada, Mississauga, ON 
NUAIRE Biological Safety Cabinet Class II Type A/B3; Thermo Electron Corp. 
Canada, Burlington, ON 
Orion Model 420A pH Meter, Thermo Electron Corp. Canada, Burlington, ON 
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Varian Eclipse Fluorescence Spectrophotometer, Varian Canada, Mississsauga, 
ON 
3.3 Methods 
3.3.1 Cell Culture: 
Normal Human Fibroblasts (HFF-1) and NPC 1 fibroblasts were maintained in 
Dulbecco's minimal essential medium (DMEM) supplemented with 10% fetal calf 
serum (FCS) and cultivated at 37 °C under an atmosphere of 5% CO2. 
3.3.2 Cloning of PFO-D4 in pTrcHisB vector and purification: 
Cloning of PFO-D4 in pTrcHisB vector was performed as mentioned in section 
2.3.2 and purification of PFO-D4 protein by Ni2+ affinity chromatography was 
performed as described in section 2.3.5. The labelling of the purified protein with 
Alexa 532 and subsequently staining on HFF-1 and NPC1 fibroblasts and imaging 
of cellular plasma membrane cholesterol was done by Dr. Shane Miersch. 
3.3.3 Preparation of cholesterol-loaded cyclodextrin: 
Excess of cholesterol (50mM) was dissolved in 1:1 (v/v) MeOH : chloroform and 
dried under a stream of argon in a glass tube. 5mM M0CD was dissolved in serum 
free DMEM and added to the dried cholesterol film and was kept under nutation 
for overnight at room temperature. The MpCD-cholesterol complex was filtered 
by 0.45um sterile filter and cholesterol was quantified. 
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3.3.4 Cholesterol analysis: 
The quantification of cholesterol loaded in cyclodextrin was done using a 
cholesterol oxidase enzymatic assay and interpolation from a standard curve. In 
brief, solubilised cholesterol is oxidized by cholesterol oxidase to the cholest-4-
en-3-one, producing hydrogen peroxide as a reaction by-product. Cholesterol 
oxidase mediated production of H2O2 is coupled to the oxidation of 10-acetyl-3,7-
dihydroxy phenoxazine to the highly fluorescent resorufin product by horseradish 
peroxidase. Cholesterol determination was performed according to the 
manufacturer's instructions to monitor resorufin formation in 96-well plate at 37 
°C with and excitation/emission couple of 545/595 nm on a Perkin Elmer Life 
Sciences Victor 3 fluorescent plate reader. 
3.3.5 Modulation of cellular plasma membrane cholesterol: 
Cellular cholesterol was augmented by treatment with cholesterol loaded methyl-
P-cyclodextrin (M0CD) adduct. In brief, IX106 cells in complete DMEM medium 
were incubated with lOOuM adduct for 1 h at 37 °C and 5% C02. Alternately, 
cellular cholesterol was depleted using an apo-MBCD. Thus, IX106 cells were 
incubated with 5 mM MBCD for 1 h at 37 °C and 5% C02 . Following cellular 
treatment, cholesterol-modulating agents were removed and the cells were used 
for experimentation. 
3.3.6 cGMP production and VASP phosphorylation as measures for 
intracellular NO signalling: 
Cells were cultivated at -85% confluence and treated with 500uM L-NMMA for 2 
h to inhibit endogenous NO production. The cells were incubated a further 2 min 
with SOD mimetic Mn(HI)TMPyP (5uM) and exposed to the NO donor DEA/NO 
(1 uM and 3 u.M) and left undisturbed for 10 min in the incubator. Cells were 
trypsinzed, collected, washed once with PBS containing 500uM DTPA and 
counted. After being adjusted for cell density (-5X105 cells/ml), the cells were 
centrifuged and lysed with buffer containing phosphodiesterase and protease 
inhibitors. The lysates were then analyzed for either cGMP with an enzyme 
immunoassay kit or VASP and phospho-VASP by Western immunoblotting with 
VASP and phosphor-VASP (Ser239) antibodies. 
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3.4 Results: 
3.4.1 Cellular Plasma Membrane Cholesterol Content Shifts the Threshold 
for NO activation of cytoplasmic Soluble Guanylyl Cyclase and the 
downstream cGMP-dependent Phosphorylation of VASP 
NPC1 fibroblasts have been shown to exhibit a marked increase in plasma 
membrane cholesterol content [Vainio, et al., 2005] and decreased membrane 
fluidity relative to normal human fibroblasts [Vainio, et al, 2005, Koike, et al, 
1998]. Therefore, NHF and NPC1 fibroblast model system was used to test the 
hypothesis that cholesterol levels in cellular plasma membranes affect NO 
signaling of intracellular targets. Activation of cytoplasmic sGC was utilized as a 
sensitive biosensor for changes in the level of extracellular NO diffusion through 
the plasma membrane. The contribution from endogenous NOS activity was 
negated by the presence of the NOS inhibitor A^-monomethyl-L-arginine (500 
uM). The levels of cGMP that accumulated in response to exogenous 1 and 3 uM 
DEA/NO exposures were 64% lower (*, p < 0.001; two-tailed t test) and 52% 
lower (*, p < 0.001; two-tailed t test), respectively, in NPC1 fibroblasts in 
comparison with that observed in an equivalent number of NHF (Fig. 3.2). When 
NHF were treated with MpCD-cholesterol to augment plasma membrane 
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cholesterol to NPC1-equivalent levels, production of cGMP elicited by subsequent 
DEA/NO exposure was similar to NPC1 fibroblast responses (Fig. 3.2, white to 
gray bars). MpCD-cholesterol treatment decreased NHF cGMP levels 72% (**,/? 
< 0.001; two-tailed t test) and 81% (**, p < 0.001; two-tailed t test) following 
either 1 or 3 uM DEA/NO exposure, respectively. In the reverse experiment, 
decreasing the plasma membrane in NPC1 by M0CD treatment increased cGMP 
production by 2.9-fold (***, p < 0.001; two-tailed t test) and 2.3-fold (***, p < 
0.001; two-tailed t test) in response to 1 and 3 uM DEA/NO, respectively. In 
contrast, when the plasma membrane was ruptured by cellular lysis immediately 
prior to DEA/NO exposure, NPC1 produced 91% (1 uM DEA/NO) and 93% (3 
uM DEA/NO) of the cGMP produced by NHF (Fig 3.3). These data support the 
hypothesis that plasma membrane cholesterol levels can modulate the degree of 
cytoplasmic sGC activation by NO. 
These data were extended to test whether variations in plasma membrane 
cholesterol affected downstream cGMP-mediated signaling. VASP is an actin-
binding regulatory protein that is a substrate for both cGMP-protein kinase (at 
Ser239) and cAMP-protein kinase (at Ser157) [Linder, et ah, 2005. Garcia, et ah, 
2002]. Consistent with cGMP data (Fig. 3.2), VASP Ser239-phosphorylation in 
NPC1 cells exposed to DEA/NO (1 uM) was 40% less (*, p = 0.033, two-tailed t 
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test) than levels observed in an equal number of identically treated NHF cells. 
Depletion of plasma membrane cholesterol from NPC1 cells with M0CD resulted 
in a proportionate increase in VASP Ser239-phosphorylation (38%; **, p = 0.087, 
two-tailed t test) following NO exposure. Conversely, augmentation of plasma 
membrane cholesterol in NHF with MpCD-cholesterol resulted in the attenuation 
VASP phosphorylation by 50% (p = 0.0034, two-tailed t test) (Fig. 3.3, A and B). 
These results clearly demonstrate that plasma membrane cholesterol content can 
influence NO engagement with intracellular targets, such as sGC, thereby 




The aim of this study was to investigate whether plasma membrane 
cholesterol levels can modulate NO diffusion and cellular signalling. Niemann-
Pick CI disease is an autosomal-recessive neurovisceral disorder characterized by 
defective endosomal cholesterol trafficking due to NPC1 gene mutation [Zhang, et 
al, 2001]. Analysis of NPC1 fibroblasts revealed increased levels of plasma 
membrane cholesterol (2 fold) and cholesterol-enriched lipid rafts (3.7 fold) 
relative to NHF (Fig. 3.1). In support of the hypothesis, cGMP levels elicited in 
NPC1 fibroblasts exposed to NO donor were -50% lower than that observed in 
their NHF counterparts (Fig. 3.2). Importantly, synthetic enrichment of NHF 
plasma membrane cholesterol (4-fold) by incubation with MBCD-cholesterol 
adducts resulted in a similar (-80%) decrease in cGMP elicited by NO compared 
with NHF with basal cholesterol (Fig. 3.2). Conversely, the depletion of plasma 
membrane cholesterol from NPC1 fibroblasts resulted in and - 2-3fold increases 
in the amount of cGMP produced. Responses to NO by both NPC1 cells and NHF 
were within 93% of each other when plasma membrane was ruptured prior to NO 
exposure. These data are consistent with a diminished capability of exogenous NO 
molecules to permeate cellular plasma membranes as a function of increased 
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cholesterol content, which was directly related to the activation of intracellular 
sGC. 
Changes in membrane cholesterol were shown to influence targets 
downstream of sGC, such as the protein kinase-G substrate VASP, a mediator of 
cell motility, angiogenesis, vascular permeability and platelet aggregation [Garcia, 
et al, 1998. Mo et al, 2004. Bellamy, et al, 2002. Ohno-Iwashita, et al, 1990]. 
Fig. 3.3 shows that the level of VASP phosphorylation elicited by NO exposure 
could be manipulated by either augmentation or depletion of plasma membrane 
cholesterol. These results suggest that hypercholesterolemia may globally infringe 
upon numerous cGMP-mediated signalling pathways. 
The spatial heterogeneity that cholesterol adds to the plasma membrane 
may act to modulate sGC at several levels. Interestingly, Ca + promotes sGC 
association with plasma membrane caveolae, specialized microdomains enriched 
with cholesterol [Linder, et al, 2005]. Due to the steep response curve of sGC to 
NO in the low nanomolar concentration range [Mo, et al, 2004. Bellamy, et al, 
2002], small decreases in NO transit through the membrane imposed by 
cholesterol could act to raise the threshold for sGC activation. In this light, 
Schmidt and co-worker found that membrane-associated sGC exhibited and 
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enhanced sensitivity to low levels of NO, whereas maximal sGC activity in 
response to high levels of NO was decreased in the membrane pool compared with 
the cytoplasmic fraction. In contrast with our findings, cholesterol depletion of 
endothelium-intact aortic rings by MBCD treatment disrupted sGC, protein kinase 
G and caveolin-1 co-localization and impaired relaxation by sGCs agonists 
[Linder, et ai, 2005]. These studies and the present data together illustrate that 
plasma membrane cholesterol is dynamically linked to sGC signalling, with the 
direction and magnitude of its effect probably determined by configurations 
unique to cell types and activation states. 
Our findings show that increased plasma membrane cholesterol content 
raises the threshold for exogenous NO to activate sGC and affect the downstream 
protein kinase G target VASP. Therefore, this study raises the possibility that the 
physical portioning of NO by membrane cholesterol rafts could be a contributing 
factor in the pathobiology of diseases beyond Niemann-Pick disorder, including 
cancer, neurodegeneration and cardiovascular diseases. 
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Figure 3.1: PM cholesterol of NHF versus NPC1 fibroblasts by fluorescence 
imaging of Alexa 532 labelled D4. Fixed normal (A) and NPC1 -deficient 
fibroblasts (C) stained with 400 nM Alexa 532-labeled D4 and imaged under 
identical exposure conditions exhibited cholesterol-dependent fluorescence. 
Normal human fibroblasts repeatedly stained less intensely than their NPC1-
deficient counterpart. Importantly, treatment of NHF with 100 uM cholesterol-
loaded MpCD was associated with an increase in cellular staining (B) and staining 
observed in NPC1-deficient cells could be largely abrogated by treatment with 
10mMM_CD prior to fixation (D). Data taken from 3-5 independently stained cell 
populations are summarized numerically from average intensities per cell for at 
least 50 cells (£). Error bars, S.D. *, /?<0.005 compared with NHF; **, p<0.001 
compared with NPC1; two-tailed t test. Cholesterol and phospholipid levels were 
determined from plasma membrane isolates obtained by sucrose gradient 
ultracentrifugation and are representative of two separate experiments with error 




Figure 3.2: Differential cGMP response of NHF and NPC1 fibroblasts to 
exogenous NO. Cyclic guanosine monophosphate was measured by an enzyme 
immunoassay following stimulation of NHF (white bars) and NPC1-deficient 
fibroblasts (black bars) with the NO donor DEA/NO (1 and 3 uM). Shown is a 
comparison of [cGMP] in NPC1 fibroblasts with that observed in an equivalent 
number of NHF (*, /?<0.001; two-tailed t test); n=3. Also shown is a comparison 
of [cGMP] in MpCD-cholesterol-treated NHF with NHF (white to gray bars; **, 
p<0.001; two-tailed t test) and a comparison of [cGMP] in MpCD-treated NPC1 
with NPC1 (gray to white bars; ***, /?<0.001; two-tailed t test); n= 3. In addition, 
[cGMP] levels in response to DEA/NO (1 and 3 uM) were compared in cell 
lysates of equal numbers of NHF and NPC1. Error bars, SD. 
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Figure 3.3: Differential VASP Ser239 phosphorylation response of NHF and 
NPC1 fibroblasts to exogenous NO. A, the amount of VASP and phospho-
Ser239 VASP was estimated from Western immunoblots using equivalent 
numbers of NHF (lanes 1-3) and NPC1 -deficient fibroblasts (lanes 4-6) probed 
with antibodies for phospho-VASP (P-VASP), VASP, and aldolase (loading 
control) in separate blots, subsequent to the exposure of the cells to DEA/NO (1 
uM) (lanes 2, 3, 5, and 6), NHF pretreated with M_CD-cholesterol (lane 3), or 
NPC1 pretreated with MpCD (lane 6). B, density plots of P-VASP data from Fig. 
5A. Comparison of phospho-VASP in NPC1 fibroblasts with that observed in an 
equivalent number of NHF (*, /?<0.033; two-tailed t test); n=2.Shownis a 
comparison of phospho-VASP in MpCD-treated NPC1 with NPC1 (gray to white 
bars; **, p< 0.087; two-tailed t test); n = 2. Also shown is a comparison of 
phospho-VASP in MpCD-cholesterol-treated NHF with NHF (white to gray bars; 
***, /?<0.0034; 2-tailed t test); n= 2. Band density was estimated with ImageJ 










Endothelial dysfunction can be induced by 
endoplasmic reticulum stress mediated inhibition 
of neutral sphingomyelinase 2. 
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4.1 Introduction: 
Endothelial dysfunction is a common occurrence in the pathogenesis of 
many cardiovascular diseases such as hypertension, coronary artery disease, 
chronic heart failure, diabetes, peripheral artery disease and chronic renal failure 
[Hua CAI, et al, 2000]. Endothelial dysfunction is also an initiation factor in 
atherosclerosis [Davignon, et al, 2004]. The hallmark of endothelial dysfunction 
which is common to all kinds of cardiovascular pathologies is the dominance of 
vasoconstriction over vasodialation in the endothelium. The pathologic 
mechanisms attributed to reduced vasodialation are reduced nitric oxide 
generation by eNOS, increased stress and hypercholesterolemia. 
Endothelial dysfunction is the outcome of various kinds of stresses around 
the endothelium- endoplasmic reticulum stress (ER stress), oxidative and 
nitrosative stress [Mete, et al, 2009. Outinen et al, 1999. De'cio, et al, 2007. 
Ohara, et al., 1993. Keaney, et al, 2005. Pa'l, et al,, 2005]. ER stress is an 
important early event in the progression of endothelium dysfunction. ER stress is 
also known to raise intracellular cholesterol thus bringing about cholesterol 
imbalance in the cell [Jin, et al, 2000. Kyosuke, et al, 1999, Werstuck, et al, 
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2001. Colgan, et al, 2007. Lee, et al, 2004. Cheng, et al, 2006]. Interestingly, the 
factors which lead to the rise in cellular cholesterol are the same which are also 
activated during ER stress. Site specific proteases SIP and S2P localized in the 
Golgi cleaves ATF6, an effecter protein responsible to restore normal ER function 
and also SREBP-2 a transcription factor when activated by cleavage upregulate 
genes for cholesterol synthesis [Jin, et al, 2000. Kyosuke, et al., 1999]. Studies 
from some groups have shown that hypercholesterolemia increases oxidative 
stress near the endothelium [Prasad, et al, 1997. Ohara, et al, 1993. Prasad, et al, 
2003]. Oxidative stress together with the nitrosative stress causes dysfunctionality 
of endothelial vessel wall in many ways. The superoxide anion produced in 
oxidative stress reacts with nitric oxide, which is produced constitutively by 
endothelial nitric oxide synthase (eNOS) leading to the formation of the strong 
oxidant peroxynitrite which attacks various biomolecules in the vascular 
endothelium, vascular smooth muscle and myocardium leading to endothelial 
dysfunction [Pa'l, et al, 2005]. 
Studies by many groups have shown that hypercholesterolemia contributes 
to abnormal endothelium-dependent vasodilation, thus bringing about endothelial 
dysfunction, which may be due to the attenuation of the eNOS activity [Robert, et 
al, 1997. Olivier, et al, 1999. Hayakama, et al, 1999. Zulli, et al, 2003]. The 
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activity of eNOS is regulated by many factors in the cell, availability of Ca2+-
calmodulin complex [Michel, et al, 1997], eNOS Ser (1179) phosphorylation 
[Yasuko, et al, 2002] and cellular localization [Carlos, et al, 2006. Qian, et al, 
2006. Davin, et al., 2005]. Impairment in any of these factors renders eNOS less 
active. Studies have revealed that where in endothelial dysfunction less eNOS 
activity may be attributed to less eNOS phosphorylation [Smith, et al, 2003 
Naoyuki, et al, 2006] or more eNOS localization in the Golgi [Mukhopadhyay, et 
al, 2007], stress can be an important contributor in lowering eNOS 
phosphorylation [Ruqin, et al., 2007] or eNOS localization in the golgi [Murata, et 
al, 2002]. 
The cellular site which needs special attention is the plasma membrane as 
it holds almost 50-90% cellular cholesterol [Lange, et al, 2000] in free or bound 
form and is also a relay station for several signal transduction pathways serving as 
an anchorage for several kinds of receptors and proteins. The point of interest in 
the current study is that plasma membrane harbours eNOS in the detergent 
resistant microdomains called caveolae where it is known to be most active and is 
also a docking site for many proteins that mediate cholesterol influx/efflux and 
intracellular trafficking to maintain cholesterol homeostasis in the cell]. Neutral 
Sphingomyelianse 2 (NSMase2) is one such protein, it is a Mg2+- dependent 
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enzyme showing optimum activity at neutral pH and is known to reside in the 
caveolae in the plasma membrane [Zhou, et al, 2004. Liza, et al, 2003. Veldman, 
et al, 2001]. There is growing evidence which suggests that NSMase2 maintains 
cellular cholesterol balance by pushing excess cholesterol to the intracellular ER 
site to be stored as cholesteryl esters [Scheek, et al, 1997. Slottle, et al, 1988. 
Liza, et al., 2003]. Apart from maintaining cholesterol balance NSMase2 is also 
known to mediate in vaso-relaxation by bringing about eNOS phosphorylation 
[Clara, et al, 2006. Barsacchi, et al, 2003. Kimiko, et al, 2005]. 
Here we present evidence showing that the inhibition of NSMase2 by 5-
nitrosation of cysteine thiols and nitration of tyrosine residues, results in the build 
up of plasma membrane cholesterol, which we have previously shown to diminish 
the trans-bilayer diffusion of NO thus limiting its bioavailability [Miersch, et al., 
2008]. We chose two of the well known ER stressors Tunicamycin (Tin) and 
Palmitate (Pm) which causes ER stress in very different ways. Tm causes ER 
stress by blocking protein glycosylation and Palmitate incorporates into ER 
membrane, disrupting the structure and integrity of ER membrane and impairment 
of SERCA resulting in depletion of Ca2+ stores. Furthermore, our data indicates 
that ER stress-mediated NSMase2 inhibition results in decreased levels of eNOS 
phosphorylation, increased eNOS localization in the Golgi and less NO 
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production. This study is first of its kind which shows how ER stress can lead to 
elevation in plasma membrane cholesterol which in turn can cause impairment of 
eNOS activity and eventually leads to endothelial dysfunction. 
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4.2 Materials and Equipment 
4.2.1 Materials 
Bovine Aortic Endothelial Cells were purchased from Coriell Research 
Repository (Camden, NJ, USA). Fetal Bovine Serum and Lipofectamine LTX 
transfection reagent were purchased from Invitrogen (Carlsbad, CA, USA). 
Streptomycin and Penicllin were purchased from GIBCO (Carlsbad, CA, USA). 
F12K medium was purchased from ATCC (Manasass, VA, USA). Tunicamycin, 
Palmitate, L-NMMA and acetylcholine were purchased from Sigma (Oakville, 
ON, Canada). U18666A, DEA/NO and GW4869 were purchased from 
Calbiochem (Los Angeles, CA, USA). 24-well glass bottom plates were purchased 
from MatTek Corporation (Ashland, MA, USA). pGIPZ NSMase2 expression 
plasmid was purchased from Open Biosystems (Huntsville, AL, USA). 
Antibodies to eNOS and phospho (Serll79) eNOS and VASP and phospho 
(Ser239) VASP were purchased from Cell Signaling Technologies (Danvers, MA, 
USA). Antibodies for GM130, GRP78/BiP, Caveolinl, p-cop, aldolase, CD36, 
SREBP-2, Nitrotyrosine, anti-rabbit phycoerythrin and anti-mouse fluorescein 
isothiocynate were purchased from Abeam Inc. (Cambridge, MA, USA). 
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Antibody to NSMase2 was purchased from Santa Cruz Biotechnolgy Inc. (Santa 
Cruz, CA, USA). Protein G beads were purchased from GE Healthcare 
(Piscataway, NJ, USA). Peroxidase conjugated streptavidin was purchased from 
Peirce (Rockford, IL, USA). Polyvinylidiene (PVDF) membrane was purchased 
from Millipore (Billerica, MA, USA). carboxy-HiDCFDA was purchased from 
Molecular Probes (Carlsbad, CA, USA). Bradford Protein assay kit was purchased 
from Bio-rad (Mississauga, ON, Canada). Sphingomyelinase assay kit was 
purchase from Echleon Inc. (Salt Lake City, UT, USA). 
4.2.2 Equipment 
Agilent 8453 UV-VIS Spectrophotometer, Agilent Technologies, Canada, Inc, 
Mississauga, ON 
Mettler AJ1000 Balance; Mettler, Toledo Canada, Mississauga, ON 
NUAIRE Biological Safety Cabinet Class II Type A/B3; Thermo Electron Corp. 
Canada, Burlington, ON 
Orion Model 420A pH Meter, Thermo Electron Corp. Canada, Burlington, ON 
Varian Eclipse Fluorescence Spectrophotometer, Varian Canada, Mississsauga, 
ON 
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Wallac 1420 Victor3 Fluorescent Plate Reader, Perkin Elmer, Woodbridge, ON 
Haemocytometer; Reichert Co, Buffalo, NY, USA 
Northern Eclipse 6.0 Imaging Software; Empix Imaging Inc., Mississauga, ON. 
Zeiss Axiovert 200 Inverted Fluorescence Microscope, Empix Imaging Inc., 
Mississauga, ON. 
Mini SDS-PAGE gel apparatus, Bio-rad, Mississauga, ON, Canada 
Sievers Nitric Oxide Analyzer (NOA) 280i, Boulder, Co, USA 
MLA-80 fixed angle rotor Optima Ultracentrifuge, Beckman Coulter Inc., 
Mississauga, ON, Canada 
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4.3 Methods 
4.3.1 Cell Culture and treatment conditions: 
Bovine Aortic Endothelial Cells, BAECs were maintained in F12K 
complete medium supplemented with 10% FBS, 100|xg/ml Streptomycin, 
lOOU/ml Penicillin. Cells from passages five to ten were used in these studies. All 
cells were maintained in a humidified incubator at 37 °C with 5% C02. The 
compounds Tunicamycin, Palmitate, L-NMMA, acetylcholine and U18666A were 
prepared fresh in culture medium, sterilized by filtration and added to the cell 
cultures. In most of the experiments the cells were treated with Tm (lOug/ml) 
and/or Palmitate (500uM) for 3 and 24 h unless mentioned, cells which were 
mock treated with culture medium at the corresponding times were taken as 
control. 
For overexpression of NSMase2, BAECs were grown to 4X104 cells per well in 
24 well glass bottom plates and transiently transfected with 5fxg of the pGIPZ 
NSMase2 expression plasmid using lOOul of the Lipofectamine LTX tranfection 
reagent and transfection was followed as per manufacturer's instructions. The 
transfection was carried out for 24 h until 80% of the cells were transfected and 
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the transient transfectants were seen for overexpression of NSMase2 by indirect 
immunofluorescence. After getting transient transfectants, the cells were thereafter 
treated with the ER stressors for the indicated time points. 
For the inhibition of NSMase2, BAECs were grown to 4X104 cells per well in 24 
well glass bottom plates and incubated with 20uM with NSMase2 inhibitor 
GW4869. NSMase2 inhibition was assessed by indirect immunofluorescence. 
Following incubation of cells with GW4869 for 30 min, the cells were treated 
with the ER stressors for the indicated time points. However, the inhibition was 
stable for upto 24 h. 
4.3.2 Animal care and treatments: 
C57BL6 mice were purchased from Charles River and were fed a standard chow 
diet (Harlan Teklad). At 15 weeks of age mice were injected intraperitoneally with 
tunicamycin (0.25ug/kg body weight) or palmitate (20ug/kg body weight) or an 
equal volume (lOOuL) of saline. After 24 h the mice were sacrificed and 
perfusion fixed and en face aortas were mounted on glass slides, as previously 
described [Khan, et ah, 2009], for further analysis. All procedures were pre-
approved by the McMaster University Animal Research Ethics Board. 
4.3.3 Plasma membrane cholesterol estimation by cholesterol specific probe 
(PFO-D4-GFPuv) and cholesterol oxidase assay: 
Imaging of Cellular Plasma Membrane Cholesterol with D4-GFPuv- The aortic 
sections and BAECs were stained with 250 nM and 1 uM of PFO-D4-GFPuv 
respectively for 30 min under 37 °C, 5% CO2, washed three times with Hepes 
buffer and imaged on an Axiovert epifluorescence microscope with 535 nm/550 
nm excitation/emission under identical exposure conditions. Images were pseudo 
colored green using Northern Eclipse 6.0 imaging software and the average 
fluorescence intensity per unit of image area was measured for 50-80 cells from 
not less than 3 independent experiments. 
Plasma membrane cholesterol analysis- Plasma membrane cholesterol isolation 
was done as described in [Miersch, et al., 2008]. Briefly, 5X105 cells/10 cm plates 
were trypsined and washed once with 100 mM Tris buffer, pH 7.4 and then with 
10 mM hypotonic Tris buffer pH 7.4. A 1 ml suspension was homogenized by 50 
strokes in a Dounce homogenizer and then spun at 190 X g for 10 min. 
Subsequently, the method described in [Vainio, et al., 2005] was followed. Lipid 
suspension isolated in buffer was extracted twice with 200 ul of 1:1 MeOH/CHCl3 
and back extracted once with 1M NaCl and the solvent was evaporated in a glass 
tube under a gentle stream of Ar. The lipid film was sonicated in 200 ul of 
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CHAPS/Triton/Sodium Cholate buffer and cholesterol was quantified using a 
cholesterol oxidase enzymatic assay and interpolated from standard curve. 
Cholesterol estimation was performed according to the manufacturer's instructions 
in a 96-well plate at 37 °C with an excitation/emission of 545 nm/595 nm on a 
Perkin Elmer Life Science Victor 3 Fluorescent plate reader. 
4.3.4 Nitric oxide release: 
BAECs were seeded at a density of 4X104 cells per well in 24 well plate and 
treated with the ER stressors for 3, 6, 12 and 24 h. There were 2 sets of cells, in 
the first set thirty minutes prior to the termination of the treatment times, the cells 
were stimulated with the Ca2+ ionophore acetylcholine (100 uM) by removing the 
culture medium and replacing with a fresh medium having acetylcholine, in the 
other set the culture medium treated with the ER stressors were left without any 
replacement with acetylcholine. The nitric oxide released was measured in the 
form of nitrite in the medium. 10 u,l of the culture medium containing nitrite was 
injected into Sievers Nitric Oxide Analyzer (Model 280i). The concentration was 
calculated by interpolation from a sodium nitrite standard curve. The NO released 
is measured by the following reactions occurring in the purge vessel. 
KI •K+ + I" 
2N02" + 21" + 4H+ • 2NO + I2 +2H20 
NO + 03 • NO*2 + 02 
N0*2 •NOj + hv 
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Nitrite reduced to NO by KI in the acidic solution rapidly reacts with ozone (O3) 
which yields NO*2 in an excited state. As the excited electron returns to the 
ground state, a photon is emitted and is detected by chemiluminescence. 
4.3.5 Endothelial nitric oxide synthase localization by double 
immunofluorescence assay and by differential sucrose density gradient 
fractionation :-
Immunocytochemistry- Formalin fixed aortic cross-sections and BAECs were 
processed for fluorescence microscopy to determine colocalization of eNOS and 
GM130 a Golgi marker. The sections and the cells were incubated with primary 
rabbit anti-eNOS and FITC conjugated anti-GM130, in a humidified chamber for 
2 h at 1:200 dilutions. Phycoerythrin conjugated anti-rabbit secondary antibody 
incubated, for 1 h at 1:400 dilutions in the humidified chamber was used to detect 
eNOS. The sections and the cells were imaged on the epifluorescence microscope 
with 495 nm/528 nm with Ex/Em for FITC and 488 nm/575 nm with Ex/Em for 
Phycoerythrin. The images were pseudocolored red and green and merged using 
Northern Eclipse 6.0 imaging software. 
Differential Sucrose Density Fractionation- Plasma membrane caveolar 
microdomains and the Golgi were prepared by differential sucrose density 
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gradient fractionation, essentially as described [Macdonald, et al., 2005] with 
slight modifications and adjustments for smaller volumes. BAECs were plated in 
10 cm culture plates were washed and scraped in phosphate buffered saline. After 
pelleting the cells for 2 min at 250xg, 1 ml of 500mM sodium carbonate, pH 11.0 
containing protease inhibitor cocktail was mixed with the pellet and incubated on 
ice for 20 min. Cells were lysed by 20 strokes in a Dounce homogenizer for 45 sec 
in a Branson sonifer 250. A step gradient of 5-30% (5% steps) sucrose with 250 
mM sodium carbonate in HBS was established in an ultracentrifuge tube (1.3 ml 
each) and the homogenate was layered on top of the gradient. After centrifugation 
at 200,000xg, 4 °C for 18 h in a MLA-80 fixed angle rotor, nine equal fractions 
were taken, starting from the top of the gradient and subjected to Trichloroacetic 
acid precipitation, gel electrophoresed and immunoblotted. 
4.3.6 Assay for Neutral Sphingomyelinase 2 activity:-
Isolation of NSMase2 from plasma membrane- Plasma membranes were prepared 
from 5 X 105 BAECs per 10 cm culture plates as previously described [Kinya, et 
al., 1976]. Purified plasma membranes were sonicated at 4 °C for 30 sec in 10 
volumes of 0.1% TritonX-100, 10 mM Tris/HCl (pH 7.5) and 0.2 mM MgC12 
with protease inhibitor cocktail. The concentration of Triton X-100 was then 
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raised to 1.0%, kept at 4 °C under rotation overnight; the membrane fraction was 
centrifuged at 30,000Xg for 10 min. The resulting supernatant containing the 
solubilised proteins was used for the immunoprecipitation of NSMase2. 25 uL of 
polyclonal rabbit anti-NSMase2 antibody was added to the supernatant and rocked 
for 90 min at 4 °C. Protein G beads which were equilibrated and precleared 
previously were added to the supernatants' and rocked for 90 min at 4 °C. The 
beads were then harvested by centrifugation at 400Xg for 5 min. The supernatant 
which did not contain any enzyme (analyzed by western blot) was discarded and 
the beads were washed once in wash buffer (20 mM Tris HC1 pH 7.5 and 0.2% 
Triton-X 100), spun down at 400Xg for 5 min. The supernatant was discarded and 
the NSMase2 was eluted with the elution buffer (20 mM Tris HC1 pH 7.5, 0.2% 
Triton-X 100 and 4% SDS) by gently rocking at 250 rpm for 15 min. The beads 
were then spun down at 400Xg for 5 min and the supernatant (si) was stored. The 
elution was carried out again for 5 min and the supernatant (s2) was stored. The 
two supernatants (s 1 & s2) were pooled together and were analyzed for NSMase2 
by western blot. Protein quantification was done by Bradford Protein assay. 
Activity- From the purified NSMase2 20ug was used to assess the activity by the 
chromogenic sphingomyelinase assay kit, lOOul of the purified enzyme was mixed 
with lOOul of the enzyme mix provided by the manufacturers in 96-well microtitre 
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plate. Briefly, the hydrolysis of sphingomyelin yielded phosphorylcholine and 
ceramide. Alkaline phosphotase catalyzed the hydrolysis of phosphorylcholine 
and choline oxidase caused oxidation of choline producing hydrogen peroxide. 
DAOS plus 4-Aminoantipyrine (4-AAP) in the presence of hydrogen peroxide and 
peroxidase resulted in the oxidative coupling of DAOS and 4-AAP to form a blue 
chromogen that was detected by measuring the absorbance of light at 595 nm. 
NSMase2 activity (mU/ml) was calculated by interpolation from the standard 
curve. 
4.3.7 S-nitrosation, denitrosation and nitration of NSMase 2:-
S-nitrosation- The isolation of NSMase2 was carried out in the same way as 
described in the section "Isolation of NSMase2 from plasma membrane" with 
difference from the elution step. The elution was carried out in the biotin switch 
blocking buffer (2.5% w/w SDS and 30 mM NEM). The beads were resuspended 
in the blocking buffer and incubated at 50 °C for 25 min with frequent vortexing. 
The beads were spun at 400Xg for 5 min and the supernatant was stored. The 
supernatant was analyzed by immunoblotting and quantified by Bradford protein 
assay. The immunoprecipitated NSMase2 was then subjected to Biotin Switch 
Assay as described in [Yanhong, et al., 2005]. Briefly, NEM was removed from 
the supernatant by precipitating the protein with 2 vol of prechilled (-20 °C) 
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ethanol, incubated at -20 °C for 1 h and centrifuged at 8000 X g, 4 °C for 10 min. 
Protein pellets were washed twice with prechilled ethanol to remove traces of 
NEM and resuspended in 0.1 ml HENS buffer per mg of protein (250 mM Hepes 
pH 7.7, 1 mM DTPA, 100 uM neocuproine, 1% SDS), ImM Biotin-HPDP and 15 
mM sodium ascorbate were added to the protein solution. The mixture was 
incubated in dark for 3 h at room temperature. The protein was precipitated and 
washed with prechilled ethanol. Protein pellets were resuspended in HENS buffer 
and mixed with 2X sample buffer without reducing agent. Protein was separated 
by SDS-PAGE, transferred to a PVDF (Millipore) membrane and incubated with 
peroxidise conjugated streptavidin (1:50,000 dilution) at 4 °C, overnight. The blot 
was developed by chemiluminescent horseradish peroxidase substrate. 
Denitrosation- NSMase2 was isolated from plasma membrane essentially the 
same as described in the "Isolation of NSMase2 from plasma membrane". The 
amount of protein in each sample was adjusted to 50fig by diluting with phosphate 
buffered saline pH 7.4 and lOu.1 of the sample was taken for the denitrosation 
assay. Denitrosation was carried out by reductive tri-iodide chemiluminescence as 
described [Peter, et al., 2007] with smaller volumes adjustments. Acidic tri-iodide 
(I3") reagent was freshly prepared with 200 mg of potassium iodide and 130 mg 
iodine in 4 ml of dH?0 and 11 ml of glacial acetic acid. lOul of the sample were 
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injected into the purge vessel containing the acidic tri-iodide reagent of Sievers 
NOA (Model 280i). The total NO released was measured by the following 
reaction in the purge vessel. 
I3" + 2RS-NO •3I+RSSR + 2NO+ 
2NO+ + 2I" •2NO + I2 
NO + 03 • NO*2 + 02 
NO*2 • N02 + hv 
The concentration was calculated by interpolation from a sodium nitrite standard 
curve. 
Nitration- The formalin fixed aortic sections were processed to determine 
nitration of NSMase2 by double immunofluorescence assay. Sections were 
incubated with primary antibodies for N02-Tyr antibody (1:100) and NSMase2 
(1:100). Secondary goat anti-mouse Phycoerythrin (1:200) and secondary donkey 
anti-rabbit FITC (1:200) were used for N02-Tyr and NSMase2 detection 
respectively. Images were captured using Axiovert epifluorescence microscope. 
The amount of nitration was also determined on immunoprecipitated NSMase2 
from plasma membrane by wertern immunoblotting with N02-Tyr antibody. 
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4.3.8 Oxidative Stress:-
A cell permeant free radical sensitive 5-(and-6)-carboxy-2',7'-
dichlorodihydrofluorescein diacetate (Carboxy-HaDCFDA) probe was used to 
measure reactive oxygen species (ROS). The cell culture supernatant and the cell 
pellets which were formed by scraping the cells in phosphate buffered saline and 
spinning at 12000 rpm for 5 min were mixed with lOOul of lOuM of carboxy-
H2DCFDA (reconstituted in PBS). The samples were loaded in 96 well microtitre 
black optical bottom plate, incubated at 37°C for 1 h and read in plate reader with 
492 nm/525 nm Excitation/Emission filter. 
4.3.9 Western Blot analysis: -
Phospho Ser (1179) eNOS, eNOS and Caveolinl- Plasma membrane caveolar 
microdomains were isolated as described above "Differential sucrose density 
fractionation". The fractions having the caveolar microdomains were pooled 
together, TCA precipitated and the protein quantification was done with Bradford 
protein assay and the protein in each sample was adjusted equal by phosphate 
bufferd saline pH 7.4. 20ug of the protein samples were mixed in SDS-PADE 
sample buffer and separated on 10% SDS PAGE gels under reducing conditions 
and transferred to PVDF membranes. Immunoblots were incubated with primary 
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antibodies to phospho Ser (1179) eNOS, eNOS and caveolinl, followed by 
appropriate horseradish peroxidase conjugated secondary. 
GRP78/BiP and SREBP-2- Cell lysates from BAECs were prepared in modified 
RIPA buffer. Protein lysates were subjected to SDS PAGE, transferred to PVDF 
membrane with primary antibodies to GRP78/BiP and SREBP-2 followed by 
horseradish peroxidase conjugated secondary. 
VASP phosphorylation- BAECs were cultivated to approximately 85% confluency 
and treated with 500uM L-NMMA for 6 h to inhibit endogenous NO production. 
The cells were treated with the ER stressors for 24 h and 2 min prior to the end of 
the treatment time the cells were incubated with luM DEA/NO and left 
undisturbed for 10 min in the incubator. Cells were lysed in the modified RIPA 
buffer containing protease inhibitor. The lysates were then analyzed for VASP and 
phospho VASP Ser239 by immunoblotting with VASP and phospho VASP Ser239 
antibodies. 
4.3.10 Statistics:-
Results are shown as a mean ± SD. Data was analysed with an impaired two-tailed 
Student's t test, a value of P < 0.05 was considered significant. 
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4.4 Results 
4.4.1 ER Stress induces the increase of cholesterol in the plasma 
membranes of BAEC and mouse aortas: 
BAEC were treated with ER stressors palmitate (Pm) and tunicamycin 
(7m). The plasma membranes were isolated by sucrose density centrifugation and 
their cholesterol content was determined by an Amplex red cholesterol assay that 
utilized cholesterol oxidase/horseradish peroxidase/ATBS. The cholesterol 
determinations indicated that the PM-cholesterol levels increased by ~4-fold to 
~5.3-fold 24h post exposure to Tm and Pm respectively (Figure 4.1 A - white 
bars). This was testified in another way where ER stressed BAECs plasma 
membrane were stained with cholesterol specific probe PFO-D4-GFP and then 
imaged under fluorescence microscope. The ER stressed BAECs showed an 
increase in plasma membrane cholesterol as viewed by the increase in the 
fluorescence of PFO-D4-GFP on the plasma membrane (Figure 4.IB). To 
determine if acute exposure to ER stress could affect membrane cholesterol in 
vivo, C57BL6 mice were injected with Pm (20u,g/Kg bodyweight), Tm 
(0.25ng/Kg bodyweight) or an equal volume of saline. Mice were sacrificed and 
aortas were removed, mounted en face and probed with PFO-D4-GFP. PFO-D4-
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GFP titrations (Figure 4.1C, 4. ID), coupled with the equation derived from KDvs. 
mol % plot (Figure 4. IB-inset), were used to estimate the changes in plasma 
membrane cholesterol upon exposure of the mice to ER stressors. 
The apparent KD estimated from for control cells was 1.2 mM. Upon Tm and Pm 
exposure these values decreased to -0.19 mM and ~0.26 mM respectively. These 
decreases in apparent KDs correspond to an estimated increase in mol % of 
cholesterol from -9.4 mol% to 58 mol% and 42 mol% respectively upon Tm and 
Pm exposure. These in vivo results are very similar to those obtained for BAEC in 
vitro (Figure 4.1 A). This was tested in another way in which aortic wall sections 
were stained with 250nM of PFO-D4-GFP which also showed increased 
fluorescence in the ER stressed aortic sections as compared to control (saline 
treated) in aortic sections (Figure 4. IE). 
4.4.2 ER Stressed cells are less responsive to extracellular NO mediated 
signaling: 
Next we tested whether ER stress mediated elevations in plasma 
membrane cholesterol affected downstream cGMP-mediated signaling. VASP is 
an actin-binding regulatory protein that is a substrate for both cGMP-protein 
kinase (at Ser239) and cAMP-protein kinase (at Ser157) [Linder, et al., 2005, 
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Garcia, et ah. 2002]. To do this, we exposed control and ER stressor exposed 
cells first to eNOS inhibitor L-NMMA for 6h then these cells were incubated for 
10 min with the NO donor DEA/NO (1 mM). The cells were then probed for the 
levels of VASP and phospho-VASP by western blotting. The ER stressed cells 
yielded ~3.5-fold and ~4.7-fold lower levels of phospho-VASP in response to 
extracellular NO indicating that elevated plasma membrane cholesterol attenuates 
the transmembrane diffusion of NO (Figure 4.2). This translates into significantly 
lower intracellular signaling by NO. 
4.4.3 Neutral Spingomyelinase 2 activity in BAEC is inhibited by nitration 
and S-nitrosation by ER stressors: 
Neutral Sphingomyelinase 2 (NSMase2) is one of the key enzymes that 
regulate plasma membrane cholesterol levels. In view of the fact that ER stressors 
increased plasma membrane cholesterol both in vivo and in vitro, we sought to 
determine whether the activity of NSMase2 in BAEC was altered by ER stress. 
Our results showed that upon 24h of exposure to Tm or Pm NSMase2 activity was 
inhibited by -40 % and ~58 % respectively (Figure 4.3A). We also exposed the 
DM enzyme to GSNO (0.1 mM) in order to S-nitrosate it. The enzyme activity 
subsequent to GSNO-exposure decreased by -82% indicating that S-nitrosation 
can inhibit the enzyme (Figure 4.3A). 
It is well established that oxidative stress is associated with the onset of 
ER stress [Celio, et al., 2009]. This was confirmed here where the levels of 
reactive oxygen species (ROS) determined by the carboxy-t^DCFDA probe 
indicated that exposure to either Tm or Pm resulted in ~3 to 4 fold increase in 
intracellular reactive oxygen species (ROS) (Figure 4. 3: B-dark gray bars) and ~ 
9 to 12 fold increase in extracellular ROS (Figure 3: B-light gray bars). 
Peroxynitrite is a highly reactive compound produced by the reaction of NO and 
superoxide, a component of ROS, that irreversibly modifies proteins by tyrosine 
nitration and/or thiol nitrosation. To determine if NSMase2 was susceptible to 
modification by peroxynitrite the NSMase2 immunoprecipitates (IPs) were probed 
by antinitrotyrosine antibodies (Figure 4.3C) and subjected to the biotin shift 
assay as well as to the direct denitrosation (i.e. release of NO from nitrosated 
thiols) of the samples in a chemiluminescent NO analyzer, to determine the thiol 
nitrosation status (Figure 4.4A, B). The IPs of NSMase2 exposed to ER stressors 
were also positive for nitrotyrosine (Figure 4.3C). 
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To determine the thiol nitrosation status of NSMase2 in vivo, the en face 
aortas of mice injected with ER stressors were co-stained with antibodies against 
nitrotyrosine and NSMase2 (Figure 4.3D). Results showed that anti-nitrotyrosine 
antibodies (red fluorescence) were colocalized (yellow fluorescence) with anti-
NSMase2 antibody (green fluorescence) (Figure 4.3D). 
In terms of thiol (S-) nitrosation status, biotin shift assay revealed that 
NSMase2 was S-nitrosated (SNO) in control cells (Figure 4.4A). This level of S-
nitrosation could be due to false positives associated with the use of ascorbate as a 
denitrosating agent in the biotin shift assay. However, upon 3h exposure to ER 
stressors the nitrosation levels (as estimated from blot densities) increased by 1.4-
to 1.6-fold. And by 24h the level of SNO-NSMase2 increased by -2.6- (7m) to 
3.1-fold (Pm) over controls (Figure 4.4B). 
As a more direct measure of determining the levels of 5-nitrosation levels 
of NSMase2, the enzyme was isolated from the control or ER stressor exposed 
samples by IP and their SNO content was determined by releasing the NO from 
the S-nitrosated thiols of NSMase2 by exposure to triiodide in a chemiluminescet 
NO analyzer (Figure 4.4C). By this method, it was evident that control enzyme 
had trace amounts of nitrosated thiols. But upon exposure to Tm or Pm the 
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amount of 5-nitrosation increased by ~ 10-fold and ~30-fold respectively These 
results strongly suggest that peroxynitite produced by ER stress-induced ROS in 
combination with endogenous NO production can inactivate NSMase2. 
4.4.4 NSMase2 overexpression or inhibition affects NO production and 
plasma membrane cholesterol levels in BAEC: 
The present data showing that NSMase2 was inhibited as a consequence of 
ER stress coupled with the established pivotal role for this enzyme in the 
modulation of plasma membrane cholesterol and NO-biosynthesis, prompted us to 
overexpress or inhibit NSMase2 in order to clarify its role in endothelial 
dysfunction. 
In control cells, the levels of plasma membrane cholesterol decreased by 
-50% upon overexpression NSMase2 (Figure 4.1 A: 24h data, black bars). The 
effects of NSMase2 overexpression on plasma membrane cholesterol were more 
dramatic in the case of the Tm and Pm treated BAEC. The cholesterol levels that 
were increased by ~4-fold and ~5-fold in the presence of Tm and Pm decreased by 
-2.5 and -3-fold upon NSMase2 overexpression (Figure 4.1 A: 24h data, black 
bars). 
The inhibition of NSMase2 with GW4869 in control cells, resulted in a 
~ 1.4-fold increase in plasma membrane cholesterol. In Tm and Pm treated BAEC, 
the inhibition of NSMase2 increased plasma membrane cholesterol levels only by 
-1.1 fold (Figure 4.1 A: 24h data, light gray bars). This is expected since ER 
stressors are already inhibiting the enzyme via nitration and 5-nitrosation (Figures 
4.3 and 4.4). 
In the case of NO production, ER stressors gradually decreased both basal 
and Ca2+ ionophore-activated NO production (detected as nitrite). For ionophore 
activated cells, exposure to Tm and Pm decreased NO production by -40 % and 
-50% by 24h. Basal NO activity decreased by -60% and -76% respectively by 
24h (Figure 4.5 A,B). 
NSMase2 overexpression had minimal (-1.1-to -1.6 fold) potentiation 
effect on ionophore-activated NO-production in control as well as Tm and Pm 
treated cells (Figure 4.5B: 24h data, black bars). However, the basal NO-
production was affected to a larger extent by NSMase2 overexpression where the 
control cells levels increased by - 1.3-fold (Figure 4.5B: 24h data, black bars). 
In case of ER stressed cells, enzyme overexpression increased the ER stress-
attenuated NO-activity by ~ 1.36-fold and ~ 1.9-fold respectively for Tm and Pm 
treated cells (Figure 4.5A: 24h data, black bars). 
4.4.5 ER stress-mediated inhibition of NSMase2 leads to decreased eNOS 
phosphorylation, and NO production but increased localization of eNOS in 
the Golgi: 
It has been established that the ceramide formed during the NSMase2 
catalyzed degradation of sphingomyelin acts as a second messenger for eNOS 
activation by phosphorylation at Ser 1179 [Clara, et al., 2006]. We therefore 
probed the phosphorylation status of BAEC-eNOS as a function of ER stress as 
well as overexpression and inhibition of NSMase. eNOS is localized in the PM as 
well as in the Golgi. We first isolated the eNOS fractions by sucrose density 
fractionation where the PM and the Golgi fractions were first identified by their 
content by the organelle markers Caveolinl and 0-Cop respectively (Figure 4.6A). 
These fractions were then probed for eNOS in the absence and presence of Tm and 
Pm. The control levels of eNOS protein in the PM increased by ~ 1.3-fold % 
between 3h and 24h. Exposure of the BAEC to Tm and Pm did not significantly 
alter eNOS levels in the PM. In contrast, Tm and Pm exposure increased Golgi-
eNOS by -1.8- and ~2.5-fold, respectively (Figure 4.6 B, C). 
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This was also determined by double immunofluorescence assay by using 
antibodies for eNOS and GM130, a Golgi resident protein and we saw that with 
ER stress more eNOS localizes in the Golgi (Figure 4.6 D). 
We next wanted to determine the extent to which ER stress as well as 
NSMase2 overexperession or inhibition affected eNOS phosphorylation at the 
PM. ER stressors Tm and Pm decreased eNOS phosphorylation by -2.5- to 5-fold 
respectively in comparison to controls. The overexpression of NSMase2 
increased phosphorylation levels by ~2-fold over wt cells. The exposure of the 
NSMase2 overexpressed BAEC to Tm and Pm decreased the phospho-eNOS by 
-60% but brought phosphorylation levels to near those observed in the wt 
enzyme. The inhibition of NSMase2 activity by GW4869 nearly abolished all 
eNOS phosphorylation in the PM (Figure 4.7). 
4.4.6 ER stress upregulates protein expression for GRP78 and SREBP-2 
with no change in Caveolinl protein expression: 
We next did western blot analysis for three proteins which may directly or 
indirectly respond during stress- GRP78/BiP, SREBP-2 and Caveolinl. 
GRP78/BiP is an ER membrane bound protein under unstressed conditions. 
During ER stress it dissociates from the ER membrane and activates other ER 
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stress effector proteins that trigger alarm and adaptive signals to restore ER 
normal functions. The protein expression for GRP78/BiP was increased as a result 
of inducing ER stress for 3, 6 and 12 h in endothelial cells. L-aldolase was used as 
a loading control and GRP78/Bip protein was quantified as a ratio with L-aldolase 
at each time points (Figure 4.8). Sterol regulatory element binding protein 
(SREBP-2) is an ER membrane bound transcription factor that upon proteolytic 
cleavage with SIP and S2P proteases can activate genes for the biosynthesis of 
cholesterol. ER stress leads to the activation of SREBP-2 and thus cholesterol 
accumulation in the cell. We determined the activated form of SREBP-2 in the 
presence of both ER stressors Tm and Palmitate. U18666A was used as a positive 
control for SREBP-2 activation. Both the ER stressors activated SREBP-2 to 
different degrees post induction in ECs (Figure 4.9). L-aldolase was used as a 
loading control and activated SREBP-2 was quantified as a ratio of L-aldolase 
expression. We next aimed at determining the protein expression for Caveolinl, it 
being an important integral membrane component of caveolae and are known to 
regulate both eNOS activity and cellular cholesterol balance. We isolated the 
caveolar membrane fractions (3&4) by differential sucrose density fractionation 
from the untreated control and ER stressed ECs. The quantification of Caveolin 1 
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protein after western blotting as a ratio of CD36 did not show any 
increase/decrease in Caveolin 1 expression after inducing ER stress (Figure 4.10). 
4.5 Discussion: 
In summary, we have demonstrated that ER stress mediated by any route 
causes a rise in plasma membrane cholesterol in endothelial cells. Accumulation 
of cholesterol leads to oxidative stress generating reactive nitrogen oxide species 
(RNOS). The RNOS causes inactivation of NSMase2 resulting in a persistent 
increase in plasma membrane cholesterol. Inactivation of NSMase2 also leads to 
the lowering of eNOS activity by reduced eNOS Ser (1179) phosphorylation. 
Another important observation made is that with ER stress more eNOS localizes 
into the Golgi. However, this localization of eNOS into Golgi is not affected by 
the inactivation of NSMase2 and presumably there is some other signalling 
pathway responsible for it. This study establishes a specific framework by which 
an imbalance in plasma membrane cholesterol and eNOS activity are related and 
translated into an endothelial dysfunction response. 
Plasma membrane is a prime site for the influx and efflux of cholesterol. 
Moreover, cholesterol synthesized in the ER is transported to the plasma 
membrane either by the Golgi complex or uses a pathway which bypasses the 
Golgi. Cholesterol endocytosed in the form of LDL- unesterified cholesterol and 
cholesteryl esters enters a complex series of endocytic compartments. The 
unesterified cholesterol is recycled back to the plasma membrane whereas 
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esterified cholesterol enters the lysosomes, where it is hydrolysed to cholesterol 
which moves to the ER to get re-esterified by ACAT and stored in cytosolic lipid 
droplets. Caveolae rafts in plasma membrane function in the uptake pathway for 
the HDL-cholesteryl esters in steroidogenic cells where cholesterol is needed in 
steroidogenesis. Exocytosis of cholesterol takes place by desorption of cell surface 
cholesterol into lipoproteins or is induced after high density lipoprotein binding to 
membrane receptors [Rothblat, et ai, 1999]. The whole process of cellular 
cholesterol synthesis, distribution and trafficking are highly regulated. This 
regulation is brought about by the SREBP-SCAP complex [Nohturfft, et ai, 
2000]. Neutral sphingomyelinase action is also implicated in cellular cholesterol 
homeostatis. Increasing cholesterol levels beyond saturation in the plasma 
membrane activates NSMase which directs excess cholesterol into the ER where 
cholesterol is esterified by ACAT and inhibits SREBP cleavage [Slotte, et ai, 
1988]. Anomaly in any of these regulators causes cholesterol imbalance which 
leads to cellular dysfunction. As evidenced in hepatic steatosis where 
hyperhomocysteinemia induces ER stress and activates SREBPs in cultured 
human hepatocytes and endothelial cells and leads to intracellular cholesterol 
accumulation [Werstuck, et al., 2001]. Also induction of ER stress in HeLa and 
MCF7 cells increased SREBP-2 expression and intracellular cholesterol 
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accumulation [Colgan, et al., 2007]. However, these studies were not extended to 
monitor the effect of ER stress on plasma membrane cholesterol. In the present 
study, we exposed BAEC to commonly employed ER stressors Tm and Pm and 
observed that plasma membrane cholesterol levels became elevated 4-5 fold 
(Figure 4.1 A). In parallel in vivo studies with mice, the onset of ER stress also 
increased plasma membrane cholesterol to a similar extent to those observed in 
vitro (Figure 4.1C,D).There was also an increase in the expression of SREBP-2 
(Figure 4.9). 
We then determined that the ER stressed cells became 3.5- to 4.7-fold less 
responsive than controls to extracellular NO-induced VASP phosphorylation one 
of the many cGMP-mediated signaling pathways. These results fully substantiate 
our earlier observations showing that the level of VASP phosphorylation elicited 
by extracellular NO exposure could be manipulated by the augmentation or 
depletion of plasma membrane cholesterol [Miersch, et al., 2008]. Our current 
study strongly suggests that ER stress-induced hypercholesterolemia can infringe 
upon various cGMP-dependent pathways by simply lowering the diffusion of NO 
across biomembranes and thus functionally lowering the bioavailability of NO. 
Hypercholesterolemia increases oxidative stress by various ways, increases 
lipid peroxidation [Prasad, et al., 1997], decreases anti-oxidant enzymes and 
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nonenzymatic antioxidants [Prasad, et al., 2003]. Hypercholesterolemia initiates 
arachidonic acid pathway enzymes lipooxygenase and cyclooxygenase and in 
vascular cells it is associated with increased O2" production by xanthine oxidase 
and NADH/NADPH oxidase. These reactive oxygen species react with nitric 
oxide and generate RNOS. RNOS brings posttransational modification of several 
proteome of endothelial cells by S-nitrosation of cysteine thiols or nitration of 
tyrosine residues. However, these modifications are reversible but they are 
involved in the inhibition of the function of the proteins [Diane et al., 2006]. In an 
effort to determine pathological mechanism behind the elevations plasma 
membrane cholesterol we focused on NSMase2, a plasma membrane outer leaflet-
resident enzyme that has been implicated in the fine regulation of plasma 
membrane cholesterol levels. We found NSMase2 activity was inhibited ~40 % 
and -58 % by exposure to Tm and Pm respectively (Figure 4.3A). We then 
compared ROS production in the BAEC and observed very large increases in both 
intracellular and extracellular ROS upon induction of ER stress (Figure 4.3B). It 
is established that ROS in combination with the NO produced by BAEC can lead 
to the formation of peroxynitrite which can irreversibly inactivate proteins by 
nitration of tyrosine residues and the oxidation and/or S-nitrosation of cysteine 
thiols. 
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Our results did indicate that NSMase2 in ER stressed BAEC or in mice 
aortas had nitrotyrosine damage indicated by Western blots or by 
immunocytochemistry (Figure 4.3 C,D). NSMase IPs from ER stressed BAEC 
were also S-nitrosated as determined by 2 independent methods. In separate 
experiments we showed that the 5-nitrosation of NSMase2 did inhibit its activity 
by -80% (Figure 4.4A,B). Taken together, these lines of evidence strongly 
suggest that NSMase2 in susceptible to inhibition by of peroxynitrite during ER 
stress. 
The next question we wanted to answer was how does the inhibition of 
NSMase2 bring about elevations in plasma membrane cholesterol? Sphingomyelin 
(SM) is preferentially localized in the outer leaflet of plasma membranes where it 
forms a 1:1 complex with cholesterol yielding microdomains termed rafts and 
caveolae. For this reason -50-90% of cellular SM and cholesterol is concentrated 
in the plasma membranes [Lange, et al., 2000]. In the plasma membrane free 
cholesterol is in equilibrium with microdomain cholesterol (Scheme I). As the 
work of Leppimaki et al. [Leppimaki, et al., 1998] has elegantly shown, total 
plasma membrane cholesterol is intimately tied to SM metabolism, the key 
enzyme in SM biosynthesis serine C- palmitoyltransferase (SPT), was activated by 
30% in cholesterol depleted cells but only slightly inhibited by 15% in cholesterol 
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loaded cells. This means that under conditions of ER stress, where cholesterol 
biosynthesis is upregulated via the SREBP pathway, SM biosynthesis will only be 
diminished by -15%. The de novo synthesized SM was shown to be efficiently 
transported to the plasma membrane [Lange, et ah, 2000] where it will combine 
with the cholesterol to form microdomains pulling the equilibrium (Scheme I) to 
the right. Under normal conditions an active NSMase2 would disrupt 
microdomains by degrading SM to choline plus ceramide, which would release the 
SM-bound cholesterol. The free cholesterol would either effluxed from the cell or 
be internalized and acylated. In this manner, the cholesterol homeostasis would be 
maintained (Scheme I). Inhibition of NSMase2 under ER stress would shift the 
equilibrium to the right thus resulting in the buildup of plasma membrane 
cholesterol rafts. The fact that under ER stress, SM-biosynthesis is slightly 
inhibited would mean that the amount of free cholesterol would also increase in 
the plasma membrane since [SM] would be limited (Scheme I). It is also possible 
that ER stress and related effects could also attenuate the efflux or internalization 
of cholesterol thus contributing to its buildup in the PM. 
We tested this hypothesis by either overexpressing or inhibiting NSMase2 in 
BAEC. As predicted the overexpression of the enzyme decreased plasma 
membrane cholesterol in control and ER stressed cells. Conversely, NSMase2 
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inhibition in control cells, increased plasma membrane cholesterol by ~ 1.4-fold. 
In the case of the ER stressed cells, where NSMase2 was already inhibited, further 
inhibition by GW4869 only increased cholesterol levels by a slight -1.1 fold. 
These studies clearly indicate that attenuation of NSMase activity can result in 
elevated plasma cholesterol. 
Hypercholesterolemia has other important manifestation which brings less 
vasodilatation of the endothelium. The abnormal vasodilatation may be due to less 
NO production and higher intracellular Ca2+ levels in smooth muscle cells 
[Roberts, et al., 1997], inhibitory effects of caveolin abundance on eNOS after 
incubating ECs with serum LDL-C from hypercholesterolemic volunteers 
[Olivier, et al., 1999], products of lipid peroxidation reduces NO bioavailability 
without affecting eNOS mass or catalytic activity in hypertension [Hayakawa, et 
al., 1999], reduced eNOS Ser (1179) phosphorylation in high cholesterol fed 
animals [Suzuki, et al., 2006]. However, all of these studies were performed 
where cholesterol was exogenously provided and there is no study till date which 
targets plasma membrane cholesterol and its subsequent effects on eNOS activity. 
In a recent study [Miersch, et al, 2008], we showed that there was an 
inverse relationship between the cholesterol content of the plasma membranes and 
the transmembrane NO-diffusion rate. In functional terms, elevations in plasma 
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membrane cholesterol translated into a significant attenuation of NO-mediated 
signalling. However, the extrapolation of these observations into common 
pathologies was not immediately obvious in view of the fact that in these studies we 
manipulated the plasma membrane cholesterol levels by chemical means or utilized 
cells from rare genetic diseases (sterol transport-defective Niemann-Pick type CI 
fibroblasts). Neutral Sphingomyelinase action on selective degradation of 
sphingomyelin, yielding bioactive lipid intermediate- ceramide is also important for 
eNOS activity. Ceramide causes eNOS Ser 1179 phosphorylation by a variety of 
kinases including Akt [Fulton, et ah, 1999] and helps in regulating arterial wall tone 
independent of intracellular Ca2+ levels [Clara, et ai, 2006]. Here, we found that 
pathophysiological conditions induced by ER stress results in less eNOS activity 
due to less eNOS Ser 1179 phosphorylation mediated by inactivation of NSMase2. 
ER stress decreased phosphorylation by -2.5 to 5-fold. The overexpression of 
NSMase2 followed by ER stress returned the phosphorylation to near wt levels. 
NSMase2 inhibition nearly abolished eNOS phosphorylation (Figure 4.7). 
These results suggest that eNOS activity, and therefore NO production, 
should be attenuated by as a consequence of ER stress mediated NSMase 
inhibition. This was indeed the case, by 24h both basal and Ca2+ ionophore-
activated NO production (detected as nitrite) decreased 50% to 76% respectively. 
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NSMase overexpression did increase basal, ER stress-inhibited activity by 1.4 to 
1.9 fold. However enzyme overexpression did not have much effect on restoring 
NO-activity in ionophore-activated cells. This suggests that under non-stimulated 
conditions a larger fraction of eNOS is de-phosphorylated [OR "not 
phosphorylated"]. 
Another important observation made in the present study was the 
localization of eNOS into the Golgi after inducing ER stress. We observed that 
although the levels of eNOS protein were essentially unaffected at the plasma 
membrane, the amount of eNOS at the Golgi increased ~2 to 3-fold upon 
induction of ER stress (Figure 4.6). We also monitored the levels of caveolin 1 
and found it not to be affected by ER stress. The functional significance of eNOS 
Golgi localization is not yet clear. In endothelial cells, eNOS localizes in the 
plasma membrane caveolar regions and in the intracellular Golgi site [Qian, et al., 
2006], eNOS within the caveolae is known to be in the most active state [Zheng et 
al., 2000]. So far, few studies have shed some light into better understanding on 
the activity of PM-eNOS versus Golgi-eNOS. During pulmonary hypertension 
less NO produced by pulmonary arterial endothelial cells is due to the localization 
of eNOS into Golgi, mainly brought by the eNOS-Golgi blockade 
[Mukhopadhyay, et al., 2007]. PM-eNOS is more accessible to agonist 
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stimulation, kinases and protein-protein interaction than the Golgi-eNOS [Qian, et 
al., 2006], which may be a reason for less NO production by Golgi-eNOS. In the 
present study, the eNOS protein levels in the caveolae were largely the same after 
ER stress and localization into Golgi remained unaltered by overexpressing and 
inhibiting NSMase2, thus suggesting that NSMase2 does not have any role in 
eNOS localization. The fact that NSMase overexpression did not restore NO 
production to control levels in ER stressed cells, coupled with the observation that 
overexpression of NSMase2 under ER stress returned the phosphorylation to near 
wt levels suggests the -50% loss in NO production is due to Golgi-trapped eNOS 
which cannot be activated by phosphorylation (Figures 4.5 and 4.7). 
However, a detailed mechanism for this localization remains to be 
established whether it occurs by the translocation of eNOS from plasma 
membrane to Golgi with the help of an eNOS traffic inducer- NOSTRIN [Kirstin, 
et al, 2002] or the "Golgi blockade hypothesis" comes into play here. The latter is 
shown where monocrotaline pyrrole induces megalocytosis and cell cycle arrest 
by blocking proteins in Golgi in endothelial cells mediated by unfolded protein 
response [Mukhopadhyay, et al, 2006]. 
Caveolinl is a coat protein for the caveolar microdomains of the plasma 
membrane. It serves as an eNOS inhibitor, forms ternary comples with eNOS and 
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NOSTRIN for the subcellular tranlocation [Schillling, et al., 2006] and is also an 
important trafficker during influx/efflux of cholesterol; it is highly upregulated 
during cholesterol loading in the cell. The caveolinl protein levels in the isolated 
plasma membrane fractions were unaffected by the ER stress. The probable 
explanation for this could be that the earlier studies where caveolin 1 was 
upregulated with cholesterol were mainly done bearing the idea of cholesterol 
transport, when cholesterol was exogenously provided or when it was effluxed to 
HDL. However, in the present study cholesterol was in situ synthesized by 
pathophysiological conditions. Moreover, as the eNOS protein content was 
unchanged in the plasma membrane after ER stress, it seems quite possible that 
caveolin 1 was not directly involved in eNOS inhibition. Taken together with our 
data, there emerges a potential link between plasma membrane cholesterol and NO 
bioavailability by eNOS as a prelude to endothelial dysfunction brought by ER 
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Figure 4.1 Cholesterol analysis on PM isolates from BAECs and titration 
of PFO-D4-GFP on aortic wall cross-sections from C57BL6 mice. (A) 
Cholesterol levels were determined from plasma membrane isolates obtained by 
sucrose gradient ultracentrifugation with lOug/ml tunicamycin (Tm), 0.5mM 
palmitate (Pm) or mock treated (C) wild type (wt) BAECs (white bars), Tm, Pm or 
C treated p-GIPZ NSMase2 transfected BAECs (black bars) and Tm, Pm or C 
treated wt- GW4869 inhibited BAECs (gray bars) for 3 and 24 h respectively. 
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Figure 4.1: (B) Visualizing cholesterol by staining with PFO-D4-GFP on 
BAECs WT, p-GIPZ NSMase2 transfected and WT-GW4869 NSMase2 inhibited 
BAECs treated with ER stressors for 24 hours and stained for plasma membrane 
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Figure 4.1 (C) Titration of aortic cross-sections with PFO-D4-GFP The aortic 
wall cross-sections from Tm treated (0.25ug/Kg bodyweight), Pm treated 
(20u.g/kg bodyweight) and saline treated (control) C57BL6 mice were titrated 
with increasing [PFO-D4-GFP]. (D) Titration of aortic wall cross-sections with 
increasing [PFO-D4-GFP] from 3 independent experiments are summarized in the 
plot and the apparent KD determined at the saturation limit of [PFO-D4-GFP]. The 
data shown is representative of 3 separate experiments with error bars showing 
S.D., * p<0.005 and ** p<0.001; two-tailed t-test. 
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Figure 4.1 (E) Aortic cross-sections stained with PFO-D4-GFP The aortic wall 
sections obtained from C57BL6 mice treated with ER stressors Tm, Palmitate 
(Pm) or mock treated (Control) were stained with PFO-D4-GFP (green) at a 
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Figure 4.2 Differential VASP Ser239 phosphorylation response of BAECs to 
exogenous NO. The amount of VASP and Dhosphor Ser239 VASP was estimated 
from western immunoblots using equivalent numbers of BAECs treated with Tm, Pm 
or mock treated (C) and probed with antibodies for VASP, Dhosphor Ser239 VASP 
and aldolase (loading control) in separate blots, subsequent to the exposure of the 
cells to DEA/NO (luM). The plot represents the density of Dhosphor Ser239 VASP 
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Figure 4.3 (A) Activity of NSMase2 IP-isolated from BAECs, effects of ROS 
generation and nitration of tyrosine residues. NSMase2 activity was measured in 
the immunoprecipitaed NSMase2 from BAECs treated with Tm, Pm or mock 
treated (C) for 24 h. IP-NSMase2 exposed to GSNO was taken as a positive control. 
(B) ROS measured by carboxy-HaDCFDA on cell culture supernatant (gray bars) 
and cell pellet (black bars) of BAECs treated with Tm, Pm and mock treated (C) for 
3 h and 24 h respectively. (C) The amount of nitration on immunoprecipitated (IP) 
NSMase2 was estimated from western immunoblots with antibodies for NC<2-Tyr 
from BAECs treated with Tm, Pm or mock treated (C) for 24 h. Immunoblot of IP-
NSMase2 was taken as the loading control. 
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Figure 4.3 (D) Double immunofluorescence assay to determine nitration on 
the aortas Nitration was determined on the aortic wall cross-sections from Tm, 
Pm or saline (Control) treated C57BL6 mice. Secondary goat anti-mouse FITC 
and secondary donkey anti-rabbit Phycoerythyrin were used for NSMase2 and 
N02-Tyr detection respectively. The data shown is representative of 2 
independent experiments with error bars showing S.D.; * p>0.005 and ** 
p>0.001; two-tailed t-test. 
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Figure 4.4 S-nitrosation and denitrosation of immunoprecipitated NSMase2 
from BAECs determined by Biotin Switch Assay and reductive tri-iodide 
chemiluminescent assay respectively. (A) NSMase2 immunoprecipitated from 
BAECs treated with Tm, Pm or mock treated (C) for 3 and 24 h respectively was 
subjected to Biotin Switch Assay. Immunoblot of immunoprecipitated (Ip-
NSMase2) was taken as loading control (B) Density plots of s-nitrosated BAECs 
treated with Tm, Pm or mock treated (C) for 3 and 24 h determined by reductive tri-
iodide chemiluminescent assay. The data is representative of 2 independent 
experiments with error bars showing S.D.; ** p>0.001; two-tailed t-test. 
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Figure 4.5 Nitric oxide production by BAECs measured in the form of total 
nitrite by Sievers Nitric Oxide Analyzer (NOA). (A) Total nitrite was measured 
with Tm, Pm or mock treated (C) wt BAECs (gray solid bars), Tm, Pm or mock 
treated p-GIPZ NSMase2 transfected BAECs (black solid bars) and Tm, Pm or 
mock treated wt- GW4869-inhibited BAECs (white bars) for 3, 6, 12 and 24 h 
respectively. (B) Thirty minutes prior to the measurement of nitrite at each time-
points the cell culture supernatant was removed and replaced with Ca-ionophore, 
acetylcholine (lOOuM) containing cell culture medium. The data shown is 
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Figure 4.6 eNOS localization determined by differential sucrose density 
fractionation and Double Immunofluorescence assay. (A) BAECs were 
subjected to differential sucrose density fractionation with a step gradient 5-30% 
(5% steps) sucrose with 250 mM sodium carbonate in Hepes buffered saline to 
determine the caveolar enriched membrane (CEM) in fractions 3 and 4 and Golgi in 
fractions 8 and 9. Immunoblots with antibodies for caveolin 1 and |3-cop were used 
to determine the organelle markers for CEM and Golgi respectively. (B) The CEM 
and Golgi fractions were pooled together from BAECs treated with Tm, Pm or 
mock treated (C) for 3 and 24 h and immunoblotted with anti-eNOS antibody. 
Immunoblots with CD36 and P-cop were used as loading controls for CEM and 
Golgi respectively. (C) Density plots of eNOS vs CD36 (gray bars) and eNOS vs 0-
cop (white bars) from Fig. 6(B). The data shown is representative of 3 independent 
experiments with error bars showing S.D. 
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Figure 4.6 (D) Double immunofluorescence assay on WT BAECS, p-GIPZ 
NSMase2 transfected BAECS and GW4869 inhibited BAECs treated with ER 
stressors for 24 h. Antibodies for GM130, a Golgi marker and eNOS were probed 
with secondary antibodies conjugated with FITC (green) and Phycoerythrin (Red). 
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Figure 4.7 eNOS Ser 1179 phosphorylation and total eNOS from isolated plasma 
membrane from BAECs. Plasma membrane isolates were obtained by sucrose 
density ultracentrifugation from Tm, Pm or mock treated (C) wt BAECs (gray 
bars), Tm, Pm or mock treated p-GIPZ Nsmase2 transfected BAECs (black solid 
bars) and Tm, Pm or mock treated wt-GW4869 inhibited BAECs (white bars) for 24 
h and immunoblotted with antibodies for eNOS, phosphor Ser 1I79 eNOS and CD36 
(loading control). Thirty min prior to the harvest of the cells the cell culture 
supernatant was removed and replaced with lOOuM acetylcholine containing 
medium. The plots represent the relative density of phosphor Ser 1179 eNOS vs 
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Figure 4.8 Western Immunoblot for GRP78/BiP Western immunoblot for ER 
stress marker GRP78/Bip from BAECs cell lysates treated with ER stressors for 3, 
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Figure 4.9. Western Immunoblot for SREBP-2 Western Immunoblot of 
SREBP-2, a transcription factor responsible for the upregulation of genes for 
cholesterol synthesis. Cell lysates from BAECs treated with ER stressors for 3 and 
24 h were immunoblotted with antibodies for SREBP-2. U18666A was used as a 
positive control and L-aldolase as loading control. P is abbreviated for precursor 













Figure 4.10. Western Immunoblot for Caveolinl Caveolin 1 immunoblot from 
caveolae enriched plasma membrane isolated from BAECs treated with ER 


























Endothelial dysfunction is associated with most forms of cardiovascular 
diseases and is also an important early event in the pathogenesis of 
atherosclerosis. The main characteristic of endothelial dysfunction which is 
common to all kinds of cardiovascular pathophysiology is the dominance of 
vasoconstriction over vasodilatation brought about by decreased biosynthesis and 
bioavailability of nitric oxide in the endothelial cell layer. The cardiovascular risk 
factors which give rise to endothelial dysfunction also cause ER stress in the 
endothelium. Interestingly, ER stress is known to upregulate genes for cholesterol 
bio-synthesis resulting in the accumulation of intracellular cholesterol. However, 
the relationship between endothelial dysfunction and ER stress is not firmly 
established and needs further investigation. 
Nitric oxide (NO) is a hydrophobic molecule and tends to partition into the 
non-aqueous milieu in the plasma membranes. In objective 1 we hypothesized that 
plasma membrane ordering provided by cholesterol affects nitric oxide diffusion 
and signalling. The findings herein showed that sterol transport-defective 
Niemann- Pick type CI (NPC1) fibroblasts which has increased plasma membrane 
cholesterol content, when exposed to exogenous NO were less responsive to 
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soluble guanylyl cyclese sGCs and subsequent cGMP production and VASP 
(Ser239) phosphorylation relative to their normal human fibroblast (NHF) 
counterparts. Furthermore, augmentation of plasma membrane cholesterol in NHF 
diminished production of both cGMP and VASP (Ser239) phosphorylation 
elicited by exogenous NO to NPC1 fibroblasts comparable levels. Conversely, 
decreasing membrane cholesterol in NPC1 fibroblasts resulted in the increased in 
both cGMP and VASP (Ser239) phosphorylation to levels similar to those 
observed in NHF. Therefore, this study raises the possibility that the physical 
partitioning of NO by membrane cholesterol rafts could be a significant 
contributing factor in the pathobiology of diseases beyond Niemann-Pick disorder, 
including cancer, neurodegeneration and cardiovascular diseases. 
The objective 2 of this thesis was to understand the underlying ER stress-
mediated mechanisms responsible for the induction of endothelial dysfunction. 
We observed that ER stress, in parallel with oxidative stress, caused elevations in 
plasma membrane cholesterol in bovine aortic endothelial cells (BAEC) as well as 
in the aortic wall of ER stressed C57BL6 mice. This study was a follow up of the 
objective 1 and here we wanted to examine the role of elevated plasma membrane 
cholesterol levels induced under pathological conditions of ER stress on the NO 
bioavailability. We observed that rise in plasma membrane cholesterol was 
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associated with decreased eNOS activity, eNOS phosphorylation and increased 
eNOS localization to the Golgi. In terms of NO bioavailability, ER stressed cells 
were 3 to 4 fold less responsive to extracellular-NO mediated signalling as 
measured by VASP phosphorylation. We also found that neutral 
sphingomyelinase 2 (NSMase2), a key enzyme in the control of plasma membrane 
cholesterol levels, was dysfunctional under conditions of ER stress as a result of 
S-nitrosation of its cysteine thiols and nitration of its tyrosine residues. In order to 
determine if the ER-stress induced effects on plasma membrane cholesterol were a 
direct consequence of altered NSMase2 activity, we over-expressed or inhibited 
the enzyme in BAEC. On the basis of these gain-and loss- of function experiments 
we observed that the over-expression of NSMase2 did decrease plasma membrane 
cholesterol while increasing basal nitric oxide levels. Conversely, the inhibition 
of this enzyme led to the attenuation of eNOS phoshorylation, NO production and 
an increase in plasma membrane cholesterol. Thus, this study signifies the role of 
neutral sphingomyelinase 2 under ER stress mediated increases in plasma 
membrane cholesterol and attenuation of endothelial NO production. 
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